Motif 1120 (n=67)
Position-wise Probabilities
Download
| uniprot | genes | site | source | protein | function |
|---|---|---|---|---|---|
| A8MTJ3 | GNAT3 | T48 | ochoa | Guanine nucleotide-binding protein G(t) subunit alpha-3 (Gustducin alpha-3 chain) | Guanine nucleotide-binding protein (G protein) alpha subunit playing a prominent role in bitter and sweet taste transduction as well as in umami (monosodium glutamate, monopotassium glutamate, and inosine monophosphate) taste transduction (PubMed:38600377, PubMed:38776963). Transduction by this alpha subunit involves coupling of specific cell-surface receptors with a cGMP-phosphodiesterase; Activation of phosphodiesterase lowers intracellular levels of cAMP and cGMP which may open a cyclic nucleotide-suppressible cation channel leading to influx of calcium, ultimately leading to release of neurotransmitter. Indeed, denatonium and strychnine induce transient reduction in cAMP and cGMP in taste tissue, whereas this decrease is inhibited by GNAT3 antibody. Gustducin heterotrimer transduces response to bitter and sweet compounds via regulation of phosphodiesterase for alpha subunit, as well as via activation of phospholipase C for beta and gamma subunits, with ultimate increase inositol trisphosphate and increase of intracellular Calcium. GNAT3 can functionally couple to taste receptors to transmit intracellular signal: receptor heterodimer TAS1R2/TAS1R3 senses sweetness and TAS1R1/TAS1R3 transduces umami taste, whereas the T2R family GPCRs such as TAS2R14 act as bitter sensors (PubMed:38600377, PubMed:38776963). Also functions as lumenal sugar sensors in the gut to control the expression of the Na+-glucose transporter SGLT1 in response to dietaty sugar, as well as the secretion of Glucagon-like peptide-1, GLP-1 and glucose-dependent insulinotropic polypeptide, GIP. Thus, may modulate the gut capacity to absorb sugars, with implications in malabsorption syndromes and diet-related disorders including diabetes and obesity. {ECO:0000269|PubMed:11917125, ECO:0000269|PubMed:17724330, ECO:0000269|PubMed:38600377, ECO:0000269|PubMed:38776963}. |
| O00506 | STK25 | T168 | ochoa | Serine/threonine-protein kinase 25 (EC 2.7.11.1) (Ste20-like kinase) (Sterile 20/oxidant stress-response kinase 1) (SOK-1) (Ste20/oxidant stress response kinase 1) | Oxidant stress-activated serine/threonine kinase that may play a role in the response to environmental stress. Targets to the Golgi apparatus where it appears to regulate protein transport events, cell adhesion, and polarity complexes important for cell migration. Part of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. STRIPAK complexes have critical roles in protein (de)phosphorylation and are regulators of multiple signaling pathways including Hippo, MAPK, nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are involved in a variety of biological processes such as cell growth, differentiation, apoptosis, metabolism and immune regulation (PubMed:18782753). {ECO:0000269|PubMed:15037601, ECO:0000269|PubMed:18782753}. |
| O14733 | MAP2K7 | S271 | psp | Dual specificity mitogen-activated protein kinase kinase 7 (MAP kinase kinase 7) (MAPKK 7) (EC 2.7.12.2) (JNK-activating kinase 2) (MAPK/ERK kinase 7) (MEK 7) (Stress-activated protein kinase kinase 4) (SAPK kinase 4) (SAPKK-4) (SAPKK4) (c-Jun N-terminal kinase kinase 2) (JNK kinase 2) (JNKK 2) | Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific role in JNK signal transduction pathway activated by pro-inflammatory cytokines. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Part of a non-canonical MAPK signaling pathway, composed of the upstream MAP3K12 kinase and downstream MAP kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated transcription of APP in response to APOE (PubMed:28111074). {ECO:0000269|PubMed:28111074, ECO:0000269|PubMed:9312068, ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930, ECO:0000269|Ref.5}. |
| O60674 | JAK2 | Y1007 | psp | Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2) | Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins (PubMed:15690087, PubMed:7615558, PubMed:9657743, PubMed:15899890). Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:15690087, PubMed:9618263). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain (PubMed:9657743). Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B) (PubMed:21368206). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:21423214). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:19783980). Up-regulates the potassium voltage-gated channel activity of KCNA3 (PubMed:25644777). {ECO:0000269|PubMed:12023369, ECO:0000269|PubMed:15690087, ECO:0000269|PubMed:19783980, ECO:0000269|PubMed:20098430, ECO:0000269|PubMed:21368206, ECO:0000269|PubMed:21423214, ECO:0000269|PubMed:25644777, ECO:0000269|PubMed:7615558, ECO:0000269|PubMed:9618263, ECO:0000269|PubMed:9657743}. |
| O94804 | STK10 | T185 | ochoa | Serine/threonine-protein kinase 10 (EC 2.7.11.1) (Lymphocyte-oriented kinase) | Serine/threonine-protein kinase involved in regulation of lymphocyte migration. Phosphorylates MSN, and possibly PLK1. Involved in regulation of lymphocyte migration by mediating phosphorylation of ERM proteins such as MSN. Acts as a negative regulator of MAP3K1/MEKK1. May also act as a cell cycle regulator by acting as a polo kinase kinase: mediates phosphorylation of PLK1 in vitro; however such data require additional evidences in vivo. {ECO:0000269|PubMed:11903060, ECO:0000269|PubMed:12639966, ECO:0000269|PubMed:19255442}. |
| P00519 | ABL1 | T392 | ochoa | Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150) | Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9 (PubMed:22810897). Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717' (PubMed:28428613). ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 also acts as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner (By similarity). Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity). Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity (By similarity). {ECO:0000250|UniProtKB:P00520, ECO:0000269|PubMed:10391250, ECO:0000269|PubMed:11971963, ECO:0000269|PubMed:12379650, ECO:0000269|PubMed:12531427, ECO:0000269|PubMed:12672821, ECO:0000269|PubMed:15031292, ECO:0000269|PubMed:15556646, ECO:0000269|PubMed:15657060, ECO:0000269|PubMed:15886098, ECO:0000269|PubMed:16424036, ECO:0000269|PubMed:16678104, ECO:0000269|PubMed:16943190, ECO:0000269|PubMed:17306540, ECO:0000269|PubMed:17623672, ECO:0000269|PubMed:18328268, ECO:0000269|PubMed:18945674, ECO:0000269|PubMed:19891780, ECO:0000269|PubMed:20357770, ECO:0000269|PubMed:20417104, ECO:0000269|PubMed:22810897, ECO:0000269|PubMed:28428613, ECO:0000269|PubMed:9037071, ECO:0000269|PubMed:9144171, ECO:0000269|PubMed:9461559}. |
| P04626 | ERBB2 | T875 | ochoa | Receptor tyrosine-protein kinase erbB-2 (EC 2.7.10.1) (Metastatic lymph node gene 19 protein) (MLN 19) (Proto-oncogene Neu) (Proto-oncogene c-ErbB-2) (Tyrosine kinase-type cell surface receptor HER2) (p185erbB2) (CD antigen CD340) | Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. {ECO:0000305}.; FUNCTION: In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth. {ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:15380516, ECO:0000269|PubMed:21555369}. |
| P04629 | NTRK1 | Y680 | ochoa|psp | High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (Tropomyosin-related kinase A) (Tyrosine kinase receptor) (Tyrosine kinase receptor A) (Trk-A) (gp140trk) (p140-TrkA) | Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand (PubMed:1281417, PubMed:15488758, PubMed:17196528, PubMed:1849459, PubMed:1850821, PubMed:22649032, PubMed:27445338, PubMed:8325889). Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival (By similarity). Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:1281417). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors. {ECO:0000250|UniProtKB:P35739, ECO:0000250|UniProtKB:Q3UFB7, ECO:0000269|PubMed:11244088, ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:1849459, ECO:0000269|PubMed:1850821, ECO:0000269|PubMed:22649032, ECO:0000269|PubMed:27445338, ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.; FUNCTION: [Isoform TrkA-III]: Resistant to NGF, it constitutively activates AKT1 and NF-kappa-B and is unable to activate the Ras-MAPK signaling cascade. Antagonizes the anti-proliferative NGF-NTRK1 signaling that promotes neuronal precursors differentiation. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. {ECO:0000269|PubMed:15488758}. |
| P04899 | GNAI2 | T48 | ochoa | Guanine nucleotide-binding protein G(i) subunit alpha-2 (Adenylate cyclase-inhibiting G alpha protein) | Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. The G(i) proteins are involved in hormonal regulation of adenylate cyclase: they inhibit the cyclase in response to beta-adrenergic stimuli. May play a role in cell division. {ECO:0000269|PubMed:17635935}.; FUNCTION: [Isoform sGi2]: Regulates the cell surface density of dopamine receptors DRD2 by sequestrating them as an intracellular pool. {ECO:0000269|PubMed:17550964}. |
| P06213 | INSR | Y1189 | ochoa|psp | Insulin receptor (IR) (EC 2.7.10.1) (CD antigen CD220) [Cleaved into: Insulin receptor subunit alpha; Insulin receptor subunit beta] | Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity). {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. |
| P07332 | FES | Y713 | ochoa|psp | Tyrosine-protein kinase Fes/Fps (EC 2.7.10.2) (Feline sarcoma/Fujinami avian sarcoma oncogene homolog) (Proto-oncogene c-Fes) (Proto-oncogene c-Fps) (p93c-fes) | Tyrosine-protein kinase that acts downstream of cell surface receptors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, cell attachment and cell spreading. Plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Acts down-stream of the activated FCER1 receptor and the mast/stem cell growth factor receptor KIT. Plays a role in the regulation of mast cell degranulation. Plays a role in the regulation of cell differentiation and promotes neurite outgrowth in response to NGF signaling. Plays a role in cell scattering and cell migration in response to HGF-induced activation of EZR. Phosphorylates BCR and down-regulates BCR kinase activity. Phosphorylates HCLS1/HS1, PECAM1, STAT3 and TRIM28. {ECO:0000269|PubMed:11509660, ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:17595334, ECO:0000269|PubMed:18046454, ECO:0000269|PubMed:19001085, ECO:0000269|PubMed:19051325, ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:2656706, ECO:0000269|PubMed:8955135}. |
| P08069 | IGF1R | Y1165 | ochoa|psp | Insulin-like growth factor 1 receptor (EC 2.7.10.1) (Insulin-like growth factor I receptor) (IGF-I receptor) (CD antigen CD221) [Cleaved into: Insulin-like growth factor 1 receptor alpha chain; Insulin-like growth factor 1 receptor beta chain] | Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.; FUNCTION: When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. |
| P08581 | MET | S1236 | ochoa | Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met) | Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of neuronal precursors, angiogenesis and kidney formation. During skeletal muscle development, it is crucial for the migration of muscle progenitor cells and for the proliferation of secondary myoblasts (By similarity). In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Also promotes differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity). {ECO:0000250|UniProtKB:P16056}.; FUNCTION: (Microbial infection) Acts as a receptor for Listeria monocytogenes internalin InlB, mediating entry of the pathogen into cells. {ECO:0000269|PubMed:11081636, ECO:0000305|PubMed:17662939, ECO:0000305|PubMed:19900460}. |
| P08754 | GNAI3 | T48 | ochoa | Guanine nucleotide-binding protein G(i) subunit alpha-3 (G(i) alpha-3) | Heterotrimeric guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signaling by an activated GPCR promotes GDP release and GTP binding. The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (By similarity). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (PubMed:18434541, PubMed:19478087, PubMed:8774883). Signaling is mediated via effector proteins, such as adenylate cyclase. Inhibits adenylate cyclase activity, leading to decreased intracellular cAMP levels (PubMed:19478087). Stimulates the activity of receptor-regulated K(+) channels (PubMed:2535845). The active GTP-bound form prevents the association of RGS14 with centrosomes and is required for the translocation of RGS14 from the cytoplasm to the plasma membrane. May play a role in cell division (PubMed:17635935). The active GTP-bound form activates the calcium permeant TRPC5 ion channels (PubMed:37137991). {ECO:0000250|UniProtKB:P08753, ECO:0000269|PubMed:17635935, ECO:0000269|PubMed:18434541, ECO:0000269|PubMed:2535845, ECO:0000269|PubMed:37137991, ECO:0000269|PubMed:8774883}. |
| P09471 | GNAO1 | T48 | ochoa | Guanine nucleotide-binding protein G(o) subunit alpha (EC 3.6.5.-) | Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:29925951, PubMed:33408414). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (By similarity). Signaling by an activated GPCR promotes GDP release and GTP binding (By similarity). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (By similarity). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (By similarity). Signaling is mediated via effector proteins, such as adenylate cyclase (By similarity). Inhibits adenylate cyclase activity, leading to decreased intracellular cAMP levels (By similarity). {ECO:0000250|UniProtKB:P18872, ECO:0000269|PubMed:29925951, ECO:0000269|PubMed:33408414}. |
| P11362 | FGFR1 | Y653 | ochoa|psp | Fibroblast growth factor receptor 1 (FGFR-1) (EC 2.7.10.1) (Basic fibroblast growth factor receptor 1) (BFGFR) (bFGF-R-1) (Fms-like tyrosine kinase 2) (FLT-2) (N-sam) (Proto-oncogene c-Fgr) (CD antigen CD331) | Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation. {ECO:0000250|UniProtKB:P16092, ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11353842, ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1379697, ECO:0000269|PubMed:1379698, ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19261810, ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753, ECO:0000269|PubMed:20139426, ECO:0000269|PubMed:21765395, ECO:0000269|PubMed:8622701, ECO:0000269|PubMed:8663044}. |
| P11488 | GNAT1 | T44 | ochoa | Guanine nucleotide-binding protein G(t) subunit alpha-1 (Transducin alpha-1 chain) | Functions as a signal transducer for the rod photoreceptor RHO. Required for normal RHO-mediated light perception by the retina (PubMed:22190596). Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs), such as the photoreceptor RHO. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Activated RHO promotes GDP release and GTP binding. Signaling is mediated via downstream effector proteins, such as cGMP-phosphodiesterase (By similarity). {ECO:0000250|UniProtKB:P04695, ECO:0000269|PubMed:22190596}. |
| P19087 | GNAT2 | T48 | ochoa | Guanine nucleotide-binding protein G(t) subunit alpha-2 (Transducin alpha-2 chain) | Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Transducin is an amplifier and one of the transducers of a visual impulse that performs the coupling between rhodopsin and cGMP-phosphodiesterase. |
| P21802 | FGFR2 | Y656 | psp | Fibroblast growth factor receptor 2 (FGFR-2) (EC 2.7.10.1) (K-sam) (KGFR) (Keratinocyte growth factor receptor) (CD antigen CD332) | Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:8663044}. |
| P22455 | FGFR4 | Y642 | ochoa|psp | Fibroblast growth factor receptor 4 (FGFR-4) (EC 2.7.10.1) (CD antigen CD334) | Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling. {ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20018895, ECO:0000269|PubMed:20683963, ECO:0000269|PubMed:20798051, ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21653700, ECO:0000269|PubMed:7518429, ECO:0000269|PubMed:7680645, ECO:0000269|PubMed:8663044}. |
| P22607 | FGFR3 | Y647 | psp | Fibroblast growth factor receptor 3 (FGFR-3) (EC 2.7.10.1) (CD antigen CD333) | Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling. {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14534538, ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:19286672, ECO:0000269|PubMed:8663044}. |
| P23458 | JAK1 | Y1034 | ochoa|psp | Tyrosine-protein kinase JAK1 (EC 2.7.10.2) (Janus kinase 1) (JAK-1) | Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed:16239216, PubMed:28111307, PubMed:32750333, PubMed:7615558, PubMed:8232552). Kinase partner for the interleukin (IL)-2 receptor (PubMed:11909529) as well as interleukin (IL)-10 receptor (PubMed:12133952). Kinase partner for the type I interferon receptor IFNAR2 (PubMed:16239216, PubMed:28111307, PubMed:32750333, PubMed:7615558, PubMed:8232552). In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins (PubMed:7759950). Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors (PubMed:16239216, PubMed:32750333, PubMed:8232552). {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:12133952, ECO:0000269|PubMed:16239216, ECO:0000269|PubMed:28111307, ECO:0000269|PubMed:32750333, ECO:0000269|PubMed:7615558, ECO:0000269|PubMed:7657660, ECO:0000269|PubMed:8232552}. |
| P29323 | EPHB2 | T779 | ochoa | Ephrin type-B receptor 2 (EC 2.7.10.1) (Developmentally-regulated Eph-related tyrosine kinase) (ELK-related tyrosine kinase) (EPH tyrosine kinase 3) (EPH-like kinase 5) (EK5) (hEK5) (Renal carcinoma antigen NY-REN-47) (Tyrosine-protein kinase TYRO5) (Tyrosine-protein kinase receptor EPH-3) [Cleaved into: EphB2/CTF1; EphB2/CTF2] | Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. In addition to axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor. May be involved in the regulation of platelet activation and blood coagulation (PubMed:30213874). {ECO:0000269|PubMed:15300251, ECO:0000269|PubMed:30213874}. |
| P29597 | TYK2 | Y1054 | psp | Non-receptor tyrosine-protein kinase TYK2 (EC 2.7.10.2) | Tyrosine kinase of the non-receptor type involved in numerous cytokines and interferons signaling, which regulates cell growth, development, cell migration, innate and adaptive immunity (PubMed:10542297, PubMed:10995743, PubMed:7657660, PubMed:7813427, PubMed:8232552). Plays both structural and catalytic roles in numerous interleukins and interferons (IFN-alpha/beta) signaling (PubMed:10542297). Associates with heterodimeric cytokine receptor complexes and activates STAT family members including STAT1, STAT3, STAT4 or STAT6 (PubMed:10542297, PubMed:7638186). The heterodimeric cytokine receptor complexes are composed of (1) a TYK2-associated receptor chain (IFNAR1, IL12RB1, IL10RB or IL13RA1), and (2) a second receptor chain associated either with JAK1 or JAK2 (PubMed:10542297, PubMed:25762719, PubMed:7526154, PubMed:7813427). In response to cytokine-binding to receptors, phosphorylates and activates receptors (IFNAR1, IL12RB1, IL10RB or IL13RA1), creating docking sites for STAT members (PubMed:7526154, PubMed:7657660). In turn, recruited STATs are phosphorylated by TYK2 (or JAK1/JAK2 on the second receptor chain), form homo- and heterodimers, translocate to the nucleus, and regulate cytokine/growth factor responsive genes (PubMed:10542297, PubMed:25762719, PubMed:7657660). Negatively regulates STAT3 activity by promototing phosphorylation at a specific tyrosine that differs from the site used for signaling (PubMed:29162862). {ECO:0000269|PubMed:10542297, ECO:0000269|PubMed:10995743, ECO:0000269|PubMed:25762719, ECO:0000269|PubMed:29162862, ECO:0000269|PubMed:7526154, ECO:0000269|PubMed:7638186, ECO:0000269|PubMed:7657660, ECO:0000269|PubMed:7813427, ECO:0000269|PubMed:8232552}. |
| P30530 | AXL | Y702 | ochoa|psp | Tyrosine-protein kinase receptor UFO (EC 2.7.10.1) (AXL oncogene) | Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, AXL binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958, ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074, ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062, ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}.; FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and lymphocytic choriomeningitis virus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:21501828, ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:25277499}.; FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. {ECO:0000269|PubMed:22673088}.; FUNCTION: (Microbial infection) Promotes Zika virus entry in glial cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:29379210, PubMed:31311882). Additionally, Zika virus potentiates AXL kinase activity to antagonize type I interferon signaling and thereby promotes infection (PubMed:28076778). Interferon signaling inhibition occurs via an SOCS1-dependent mechanism (PubMed:29379210). {ECO:0000269|PubMed:28076778, ECO:0000269|PubMed:29379210, ECO:0000269|PubMed:31311882}. |
| P33981 | TTK | T676 | psp | Dual specificity protein kinase TTK (EC 2.7.12.1) (Phosphotyrosine picked threonine-protein kinase) (PYT) | Involved in mitotic spindle assembly checkpoint signaling, a process that delays anaphase until chromosomes are bioriented on the spindle, and in the repair of incorrect mitotic kinetochore-spindle microtubule attachments (PubMed:18243099, PubMed:28441529, PubMed:29162720). Phosphorylates MAD1L1 to promote the mitotic spindle assembly checkpoint (PubMed:18243099, PubMed:29162720). Phosphorylates CDCA8/Borealin leading to enhanced AURKB activity at the kinetochore (PubMed:18243099). Phosphorylates SKA3 at 'Ser-34' leading to dissociation of the SKA complex from microtubules and destabilization of microtubule-kinetochore attachments (PubMed:28441529). Phosphorylates KNL1, KNTC1 and autophosphorylates (PubMed:28441529). Phosphorylates MCRS1 which enhances recruitment of KIF2A to the minus end of spindle microtubules and promotes chromosome alignment (PubMed:30785839). {ECO:0000269|PubMed:18243099, ECO:0000269|PubMed:28441529, ECO:0000269|PubMed:29162720, ECO:0000269|PubMed:30785839}. |
| P36507 | MAP2K2 | S222 | ochoa|psp | Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2) | Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126). {ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:29433126}. |
| P42684 | ABL2 | T438 | ochoa | Tyrosine-protein kinase ABL2 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 2) (Abelson tyrosine-protein kinase 2) (Abelson-related gene protein) (Tyrosine-protein kinase ARG) | Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 also acts as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity). {ECO:0000250|UniProtKB:Q4JIM5, ECO:0000269|PubMed:15735735, ECO:0000269|PubMed:15886098, ECO:0000269|PubMed:16678104, ECO:0000269|PubMed:17306540, ECO:0000269|PubMed:18945674}. |
| P43403 | ZAP70 | Y492 | ochoa|psp | Tyrosine-protein kinase ZAP-70 (EC 2.7.10.2) (70 kDa zeta-chain associated protein) (Syk-related tyrosine kinase) | Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. Also contributes to the development and activation of primary B-lymphocytes. When antigen presenting cells (APC) activate T-cell receptor (TCR), a serie of phosphorylations lead to the recruitment of ZAP70 to the doubly phosphorylated TCR component CD247/CD3Z through ITAM motif at the plasma membrane. This recruitment serves to localization to the stimulated TCR and to relieve its autoinhibited conformation. Release of ZAP70 active conformation is further stabilized by phosphorylation mediated by LCK. Subsequently, ZAP70 phosphorylates at least 2 essential adapter proteins: LAT and LCP2. In turn, a large number of signaling molecules are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Furthermore, ZAP70 controls cytoskeleton modifications, adhesion and mobility of T-lymphocytes, thus ensuring correct delivery of effectors to the APC. ZAP70 is also required for TCR-CD247/CD3Z internalization and degradation through interaction with the E3 ubiquitin-protein ligase CBL and adapter proteins SLA and SLA2. Thus, ZAP70 regulates both T-cell activation switch on and switch off by modulating TCR expression at the T-cell surface. During thymocyte development, ZAP70 promotes survival and cell-cycle progression of developing thymocytes before positive selection (when cells are still CD4/CD8 double negative). Additionally, ZAP70-dependent signaling pathway may also contribute to primary B-cells formation and activation through B-cell receptor (BCR). {ECO:0000269|PubMed:11353765, ECO:0000269|PubMed:12051764, ECO:0000269|PubMed:1423621, ECO:0000269|PubMed:20135127, ECO:0000269|PubMed:26903241, ECO:0000269|PubMed:38614099, ECO:0000269|PubMed:8124727, ECO:0000269|PubMed:8702662, ECO:0000269|PubMed:9489702}. |
| P43405 | SYK | Y525 | ochoa|psp | Tyrosine-protein kinase SYK (EC 2.7.10.2) (Spleen tyrosine kinase) (p72-Syk) | Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development (PubMed:12387735, PubMed:33782605). Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include DEPTOR, VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK (PubMed:12456653, PubMed:15388330, PubMed:34634301, PubMed:8657103). Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition (PubMed:12456653). Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR also plays a role in T-cell receptor signaling. Also plays a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade (By similarity). Required for the stimulation of neutrophil phagocytosis by IL15 (PubMed:15123770). Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Involved in interleukin-3/IL3-mediated signaling pathway in basophils (By similarity). Also functions downstream of receptors mediating cell adhesion (PubMed:12387735). Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Also plays a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response (By similarity). {ECO:0000250|UniProtKB:P48025, ECO:0000269|PubMed:12387735, ECO:0000269|PubMed:12456653, ECO:0000269|PubMed:15123770, ECO:0000269|PubMed:15388330, ECO:0000269|PubMed:19909739, ECO:0000269|PubMed:33782605, ECO:0000269|PubMed:34634301, ECO:0000269|PubMed:8657103, ECO:0000269|PubMed:9535867}. |
| P45985 | MAP2K4 | S257 | ochoa|psp | Dual specificity mitogen-activated protein kinase kinase 4 (MAP kinase kinase 4) (MAPKK 4) (EC 2.7.12.2) (JNK-activating kinase 1) (MAPK/ERK kinase 4) (MEK 4) (SAPK/ERK kinase 1) (SEK1) (Stress-activated protein kinase kinase 1) (SAPK kinase 1) (SAPKK-1) (SAPKK1) (c-Jun N-terminal kinase kinase 1) (JNKK) | Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to pro-inflammatory cytokines, while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269|PubMed:7716521}. |
| P46734 | MAP2K3 | S218 | ochoa|psp | Dual specificity mitogen-activated protein kinase kinase 3 (MAP kinase kinase 3) (MAPKK 3) (EC 2.7.12.2) (MAPK/ERK kinase 3) (MEK 3) (Stress-activated protein kinase kinase 2) (SAPK kinase 2) (SAPKK-2) (SAPKK2) | Dual specificity kinase. Is activated by cytokines and environmental stress in vivo. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in the MAP kinase p38. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14. {ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8622669}. |
| P52333 | JAK3 | Y980 | psp | Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) | Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A and STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion. {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:20440074, ECO:0000269|PubMed:7662955, ECO:0000269|PubMed:8022485}. |
| P52564 | MAP2K6 | S207 | ochoa|psp | Dual specificity mitogen-activated protein kinase kinase 6 (MAP kinase kinase 6) (MAPKK 6) (EC 2.7.12.2) (MAPK/ERK kinase 6) (MEK 6) (Stress-activated protein kinase kinase 3) (SAPK kinase 3) (SAPKK-3) (SAPKK3) | Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in the MAP kinases p38 MAPK11, MAPK12, MAPK13 and MAPK14 and plays an important role in the regulation of cellular responses to cytokines and all kinds of stresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are both essential for the activation of MAPK11 and MAPK13 induced by environmental stress, whereas MAP2K6/MKK6 is the major MAPK11 activator in response to TNF. MAP2K6/MKK6 also phosphorylates and activates PAK6. The p38 MAP kinase signal transduction pathway leads to direct activation of transcription factors. Nuclear targets of p38 MAP kinase include the transcription factors ATF2 and ELK1. Within the p38 MAPK signal transduction pathway, MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14 activation, and is therefore required for STAT4 activation and STAT4-regulated gene expression in response to IL-12 stimulation. The pathway is also crucial for IL-6-induced SOCS3 expression and down-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclast differentiation through NF-kappa-B transactivation by TNFSF11, and in endochondral ossification and since SOX9 is another likely downstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediates apoptotic cell death in thymocytes. Acts also as a regulator for melanocytes dendricity, through the modulation of Rho family GTPases. {ECO:0000269|PubMed:10961885, ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393, ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669, ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074, ECO:0000269|PubMed:9218798}. |
| P54753 | EPHB3 | T791 | ochoa | Ephrin type-B receptor 3 (EC 2.7.10.1) (EPH-like tyrosine kinase 2) (EPH-like kinase 2) (Embryonic kinase 2) (EK2) (hEK2) (Tyrosine-protein kinase TYRO6) | Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Generally has an overlapping and redundant function with EPHB2. Like EPHB2, functions in axon guidance during development regulating for instance the neurons forming the corpus callosum and the anterior commissure, 2 major interhemispheric connections between the temporal lobes of the cerebral cortex. In addition to its role in axon guidance also plays an important redundant role with other ephrin-B receptors in development and maturation of dendritic spines and the formation of excitatory synapses. Controls other aspects of development through regulation of cell migration and positioning. This includes angiogenesis, palate development and thymic epithelium development for instance. Forward and reverse signaling through the EFNB2/EPHB3 complex also regulate migration and adhesion of cells that tubularize the urethra and septate the cloaca. Finally, plays an important role in intestinal epithelium differentiation segregating progenitor from differentiated cells in the crypt. {ECO:0000269|PubMed:15536074}. |
| P54760 | EPHB4 | T773 | ochoa | Ephrin type-B receptor 4 (EC 2.7.10.1) (Hepatoma transmembrane kinase) (Tyrosine-protein kinase TYRO11) | Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 it is involved in the regulation of cell adhesion and migration, and plays a central role in heart morphogenesis, angiogenesis and blood vessel remodeling and permeability. EPHB4-mediated forward signaling controls cellular repulsion and segregation from EFNB2-expressing cells. {ECO:0000269|PubMed:12734395, ECO:0000269|PubMed:16424904, ECO:0000269|PubMed:27400125, ECO:0000269|PubMed:30578106}. |
| P63096 | GNAI1 | T48 | ochoa | Guanine nucleotide-binding protein G(i) subunit alpha-1 (EC 3.6.5.-) (Adenylate cyclase-inhibiting G alpha protein) | Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:18434541, PubMed:33762731, PubMed:34239069, PubMed:35610220, PubMed:37935376, PubMed:37935377, PubMed:37963465, PubMed:38552625, PubMed:8774883, PubMed:38918398). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (PubMed:18434541, PubMed:8774883). Signaling by an activated GPCR promotes GDP release and GTP binding (PubMed:18434541, PubMed:8774883). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (PubMed:18434541, PubMed:8774883). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (PubMed:18434541, PubMed:8774883). Signaling is mediated via effector proteins, such as adenylate cyclase: inhibits adenylate cyclase activity of ADCY1, ADCY5 and ADCY6, leading to decreased intracellular cAMP levels (PubMed:8119955). The inactive GDP-bound form prevents the association of RGS14 with centrosomes and is required for the translocation of RGS14 from the cytoplasm to the plasma membrane. Required for normal cytokinesis during mitosis (PubMed:17635935). Required for cortical dynein-dynactin complex recruitment during metaphase (PubMed:22327364). {ECO:0000250|UniProtKB:P10824, ECO:0000269|PubMed:17635935, ECO:0000269|PubMed:18434541, ECO:0000269|PubMed:22327364, ECO:0000269|PubMed:33762731, ECO:0000269|PubMed:34239069, ECO:0000269|PubMed:35610220, ECO:0000269|PubMed:37935376, ECO:0000269|PubMed:37935377, ECO:0000269|PubMed:37963465, ECO:0000269|PubMed:38552625, ECO:0000269|PubMed:38918398, ECO:0000269|PubMed:8119955, ECO:0000269|PubMed:8774883}. |
| P68363 | TUBA1B | T73 | ochoa | Tubulin alpha-1B chain (EC 3.6.5.-) (Alpha-tubulin ubiquitous) (Tubulin K-alpha-1) (Tubulin alpha-ubiquitous chain) [Cleaved into: Detyrosinated tubulin alpha-1B chain] | Tubulin is the major constituent of microtubules, protein filaments consisting of alpha- and beta-tubulin heterodimers (PubMed:38305685, PubMed:34996871, PubMed:38609661). Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms (PubMed:38305685, PubMed:34996871, PubMed:38609661). Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin (PubMed:34996871, PubMed:38609661). {ECO:0000269|PubMed:34996871, ECO:0000269|PubMed:38305685, ECO:0000269|PubMed:38609661}. |
| Q02750 | MAP2K1 | S218 | ochoa|psp | Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1) | Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111, ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:29433126}. |
| Q05397 | PTK2 | T575 | ochoa | Focal adhesion kinase 1 (FADK 1) (EC 2.7.10.2) (Focal adhesion kinase-related nonkinase) (FRNK) (Protein phosphatase 1 regulatory subunit 71) (PPP1R71) (Protein-tyrosine kinase 2) (p125FAK) (pp125FAK) | Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development and placenta development. Required for embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. Regulates axon growth and neuronal cell migration, axon branching and synapse formation; required for normal development of the nervous system. Plays a role in osteogenesis and differentiation of osteoblasts. Functions in integrin signal transduction, but also in signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), EPHA2, netrin receptors and LDL receptors. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascade. Promotes activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling cascade. Promotes localized and transient activation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), and thereby modulates the activity of Rho family GTPases. Signaling via CAS family members mediates activation of RAC1. Phosphorylates NEDD9 following integrin stimulation (PubMed:9360983). Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ACTN1, ARHGEF7, GRB7, RET and WASL. Promotes phosphorylation of PXN and STAT1; most likely PXN and STAT1 are phosphorylated by a SRC family kinase that is recruited to autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself. Promotes phosphorylation of BCAR1; GIT2 and SHC1; this requires both SRC and PTK2/FAK1. Promotes phosphorylation of BMX and PIK3R1. Isoform 6 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced expression can attenuate the nuclear accumulation of LPXN and limit its ability to enhance serum response factor (SRF)-dependent gene transcription. {ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:11980671, ECO:0000269|PubMed:15166238, ECO:0000269|PubMed:15561106, ECO:0000269|PubMed:15895076, ECO:0000269|PubMed:16919435, ECO:0000269|PubMed:16927379, ECO:0000269|PubMed:17395594, ECO:0000269|PubMed:17431114, ECO:0000269|PubMed:17968709, ECO:0000269|PubMed:18006843, ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:18256281, ECO:0000269|PubMed:18292575, ECO:0000269|PubMed:18497331, ECO:0000269|PubMed:18677107, ECO:0000269|PubMed:19138410, ECO:0000269|PubMed:19147981, ECO:0000269|PubMed:19224453, ECO:0000269|PubMed:20332118, ECO:0000269|PubMed:20495381, ECO:0000269|PubMed:21454698, ECO:0000269|PubMed:9360983}.; FUNCTION: [Isoform 6]: Isoform 6 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced expression can attenuate the nuclear accumulation of LPXN and limit its ability to enhance serum response factor (SRF)-dependent gene transcription. {ECO:0000269|PubMed:20109444}. |
| Q08345 | DDR1 | Y796 | ochoa|psp | Epithelial discoidin domain-containing receptor 1 (Epithelial discoidin domain receptor 1) (EC 2.7.10.1) (CD167 antigen-like family member A) (Cell adhesion kinase) (Discoidin receptor tyrosine kinase) (HGK2) (Mammary carcinoma kinase 10) (MCK-10) (Protein-tyrosine kinase 3A) (Protein-tyrosine kinase RTK-6) (TRK E) (Tyrosine kinase DDR) (Tyrosine-protein kinase CAK) (CD antigen CD167a) | Tyrosine kinase that functions as a cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation. Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates cell migration and wound healing. Required for normal blastocyst implantation during pregnancy, for normal mammary gland differentiation and normal lactation. Required for normal ear morphology and normal hearing (By similarity). Promotes smooth muscle cell migration, and thereby contributes to arterial wound healing. Also plays a role in tumor cell invasion. Phosphorylates PTPN11. {ECO:0000250, ECO:0000269|PubMed:12065315, ECO:0000269|PubMed:16234985, ECO:0000269|PubMed:16337946, ECO:0000269|PubMed:19401332, ECO:0000269|PubMed:20093046, ECO:0000269|PubMed:20432435, ECO:0000269|PubMed:20884741, ECO:0000269|PubMed:21044884, ECO:0000269|PubMed:9659899}. |
| Q12866 | MERTK | Y753 | psp | Tyrosine-protein kinase Mer (EC 2.7.10.1) (Proto-oncogene c-Mer) (Receptor tyrosine kinase MerTK) | Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). Ligand binding at the cell surface induces autophosphorylation of MERTK on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment (PubMed:32640697). Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3. {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:32640697}. |
| Q13043 | STK4 | T177 | ochoa|psp | Serine/threonine-protein kinase 4 (EC 2.7.11.1) (Mammalian STE20-like protein kinase 1) (MST-1) (STE20-like kinase MST1) (Serine/threonine-protein kinase Krs-2) [Cleaved into: Serine/threonine-protein kinase 4 37kDa subunit (MST1/N); Serine/threonine-protein kinase 4 18kDa subunit (MST1/C)] | Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation. Key component of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. STK3/MST2 and STK4/MST1 are required to repress proliferation of mature hepatocytes, to prevent activation of facultative adult liver stem cells (oval cells), and to inhibit tumor formation (By similarity). Phosphorylates 'Ser-14' of histone H2B (H2BS14ph) during apoptosis. Phosphorylates FOXO3 upon oxidative stress, which results in its nuclear translocation and cell death initiation. Phosphorylates MOBKL1A, MOBKL1B and RASSF2. Phosphorylates TNNI3 (cardiac Tn-I) and alters its binding affinity to TNNC1 (cardiac Tn-C) and TNNT2 (cardiac Tn-T). Phosphorylates FOXO1 on 'Ser-212' and regulates its activation and stimulates transcription of PMAIP1 in a FOXO1-dependent manner. Phosphorylates SIRT1 and inhibits SIRT1-mediated p53/TP53 deacetylation, thereby promoting p53/TP53 dependent transcription and apoptosis upon DNA damage. Acts as an inhibitor of PKB/AKT1. Phosphorylates AR on 'Ser-650' and suppresses its activity by intersecting with PKB/AKT1 signaling and antagonizing formation of AR-chromatin complexes. {ECO:0000250|UniProtKB:Q9JI11, ECO:0000269|PubMed:11278283, ECO:0000269|PubMed:11517310, ECO:0000269|PubMed:12757711, ECO:0000269|PubMed:15109305, ECO:0000269|PubMed:16510573, ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:16930133, ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:18328708, ECO:0000269|PubMed:18986304, ECO:0000269|PubMed:19525978, ECO:0000269|PubMed:21212262, ECO:0000269|PubMed:21245099, ECO:0000269|PubMed:21512132, ECO:0000269|PubMed:8702870, ECO:0000269|PubMed:8816758}. |
| Q13163 | MAP2K5 | S311 | ochoa|psp | Dual specificity mitogen-activated protein kinase kinase 5 (MAP kinase kinase 5) (MAPKK 5) (EC 2.7.12.2) (MAPK/ERK kinase 5) (MEK 5) | Acts as a scaffold for the formation of a ternary MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex. Activation of this pathway appears to play a critical role in protecting cells from stress-induced apoptosis, neuronal survival and cardiac development and angiogenesis. As part of the MAPK/ERK signaling pathway, acts as a negative regulator of apoptosis in cardiomyocytes via promotion of STUB1/CHIP-mediated ubiquitination and degradation of ICER-type isoforms of CREM (By similarity). {ECO:0000250|UniProtKB:Q62862, ECO:0000269|PubMed:7759517, ECO:0000269|PubMed:9384584}. |
| Q13188 | STK3 | T174 | ochoa | Serine/threonine-protein kinase 3 (EC 2.7.11.1) (Mammalian STE20-like protein kinase 2) (MST-2) (STE20-like kinase MST2) (Serine/threonine-protein kinase Krs-1) [Cleaved into: Serine/threonine-protein kinase 3 36kDa subunit (MST2/N); Serine/threonine-protein kinase 3 20kDa subunit (MST2/C)] | Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation (PubMed:11278283, PubMed:8566796, PubMed:8816758). Key component of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ (PubMed:15688006, PubMed:16930133, PubMed:23972470, PubMed:28087714, PubMed:29063833, PubMed:30622739). Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration (PubMed:15688006, PubMed:16930133, PubMed:23972470, PubMed:28087714). STK3/MST2 and STK4/MST1 are required to repress proliferation of mature hepatocytes, to prevent activation of facultative adult liver stem cells (oval cells), and to inhibit tumor formation. Phosphorylates NKX2-1 (By similarity). Phosphorylates NEK2 and plays a role in centrosome disjunction by regulating the localization of NEK2 to centrosome, and its ability to phosphorylate CROCC and CEP250 (PubMed:21076410, PubMed:21723128). In conjunction with SAV1, activates the transcriptional activity of ESR1 through the modulation of its phosphorylation (PubMed:21104395). Positively regulates RAF1 activation via suppression of the inhibitory phosphorylation of RAF1 on 'Ser-259' (PubMed:20212043). Phosphorylates MOBKL1A and RASSF2 (PubMed:19525978). Phosphorylates MOBKL1B on 'Thr-74'. Acts cooperatively with MOBKL1B to activate STK38 (PubMed:18328708, PubMed:18362890). {ECO:0000250|UniProtKB:Q9JI10, ECO:0000269|PubMed:11278283, ECO:0000269|PubMed:15688006, ECO:0000269|PubMed:16930133, ECO:0000269|PubMed:18328708, ECO:0000269|PubMed:18362890, ECO:0000269|PubMed:19525978, ECO:0000269|PubMed:20212043, ECO:0000269|PubMed:21076410, ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21723128, ECO:0000269|PubMed:23972470, ECO:0000269|PubMed:28087714, ECO:0000269|PubMed:29063833, ECO:0000269|PubMed:30622739, ECO:0000269|PubMed:8566796, ECO:0000269|PubMed:8816758}. |
| Q16512 | PKN1 | Y768 | ochoa | Serine/threonine-protein kinase N1 (EC 2.7.11.13) (Protease-activated kinase 1) (PAK-1) (Protein kinase C-like 1) (Protein kinase C-like PKN) (Protein kinase PKN-alpha) (Protein-kinase C-related kinase 1) (Serine-threonine protein kinase N) | PKC-related serine/threonine-protein kinase involved in various processes such as regulation of the intermediate filaments of the actin cytoskeleton, cell migration, tumor cell invasion and transcription regulation. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14. Regulates the cytoskeletal network by phosphorylating proteins such as VIM and neurofilament proteins NEFH, NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to bind to microtubules, resulting in disruption of tubulin assembly. Acts as a key coactivator of androgen receptor (AR)-dependent transcription, by being recruited to AR target genes and specifically mediating phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for epigenetic transcriptional activation that promotes demethylation of histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, HDAC7 and HDAC9, leading to impair their import in the nucleus. Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. {ECO:0000269|PubMed:11104762, ECO:0000269|PubMed:12514133, ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:18066052, ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:24248594, ECO:0000269|PubMed:8557118, ECO:0000269|PubMed:8621664, ECO:0000269|PubMed:9175763}. |
| Q16620 | NTRK2 | Y706 | psp | BDNF/NT-3 growth factors receptor (EC 2.7.10.1) (GP145-TrkB) (Trk-B) (Neurotrophic tyrosine kinase receptor type 2) (TrkB tyrosine kinase) (Tropomyosin-related kinase B) | Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity (By similarity). Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2 (PubMed:15494731, PubMed:7574684). Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:15494731). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia. {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731, ECO:0000269|PubMed:7574684}. |
| Q16832 | DDR2 | Y740 | psp | Discoidin domain-containing receptor 2 (Discoidin domain receptor 2) (EC 2.7.10.1) (CD167 antigen-like family member B) (Discoidin domain-containing receptor tyrosine kinase 2) (Neurotrophic tyrosine kinase, receptor-related 3) (Receptor protein-tyrosine kinase TKT) (Tyrosine-protein kinase TYRO10) (CD antigen CD167b) | Tyrosine kinase involved in the regulation of tissues remodeling (PubMed:30449416). It functions as a cell surface receptor for fibrillar collagen and regulates cell differentiation, remodeling of the extracellular matrix, cell migration and cell proliferation. Required for normal bone development. Regulates osteoblast differentiation and chondrocyte maturation via a signaling pathway that involves MAP kinases and leads to the activation of the transcription factor RUNX2. Regulates remodeling of the extracellular matrix by up-regulation of the collagenases MMP1, MMP2 and MMP13, and thereby facilitates cell migration and tumor cell invasion. Promotes fibroblast migration and proliferation, and thereby contributes to cutaneous wound healing. {ECO:0000269|PubMed:16186104, ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:17665456, ECO:0000269|PubMed:18201965, ECO:0000269|PubMed:20004161, ECO:0000269|PubMed:20564243, ECO:0000269|PubMed:20734453, ECO:0000269|PubMed:30449416, ECO:0000269|PubMed:9659899}. |
| Q71U36 | TUBA1A | T73 | ochoa | Tubulin alpha-1A chain (EC 3.6.5.-) (Alpha-tubulin 3) (Tubulin B-alpha-1) (Tubulin alpha-3 chain) [Cleaved into: Detyrosinated tubulin alpha-1A chain] | Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin. |
| Q8N4C8 | MINK1 | T181 | ochoa | Misshapen-like kinase 1 (EC 2.7.11.1) (GCK family kinase MiNK) (MAPK/ERK kinase kinase kinase 6) (MEK kinase kinase 6) (MEKKK 6) (Misshapen/NIK-related kinase) (Mitogen-activated protein kinase kinase kinase kinase 6) | Serine/threonine kinase which acts as a negative regulator of Ras-related Rap2-mediated signal transduction to control neuronal structure and AMPA receptor trafficking (PubMed:10708748, PubMed:16337592). Required for normal synaptic density, dendrite complexity, as well as surface AMPA receptor expression in hippocampal neurons (By similarity). Can activate the JNK and MAPK14/p38 pathways and mediates stimulation of the stress-activated protein kinase MAPK14/p38 MAPK downstream of the Raf/ERK pathway. Phosphorylates TANC1 upon stimulation by RAP2A, MBP and SMAD1 (PubMed:18930710, PubMed:21690388). Has an essential function in negative selection of thymocytes, perhaps by coupling NCK1 to activation of JNK1 (By similarity). Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:26437443). {ECO:0000250|UniProtKB:F1LP90, ECO:0000250|UniProtKB:Q9JM52, ECO:0000269|PubMed:10708748, ECO:0000269|PubMed:16337592, ECO:0000269|PubMed:18930710, ECO:0000269|PubMed:21690388, ECO:0000269|PubMed:26437443}.; FUNCTION: Isoform 4 can activate the JNK pathway. Involved in the regulation of actin cytoskeleton reorganization, cell-matrix adhesion, cell-cell adhesion and cell migration. |
| Q8NEV4 | MYO3A | T178 | psp | Myosin-IIIa (EC 2.7.11.1) | Actin-dependent motor protein with a protein kinase activity, playing an essential role in hearing (PubMed:12032315, PubMed:29880844, PubMed:34788109). Probably also plays a role in vision. Required for normal cochlear hair bundle development and hearing. Plays an important role in the early steps of cochlear hair bundle morphogenesis. Influences the number and lengths of stereocilia to be produced and limits the growth of microvilli within the forming auditory hair bundles thereby contributing to the architecture of the hair bundle, including its staircase pattern. Involved in the elongation of actin in stereocilia tips by transporting the actin regulatory factor ESPN to the plus ends of actin filaments (PubMed:29880844, PubMed:34788109). {ECO:0000250|UniProtKB:Q8K3H5, ECO:0000269|PubMed:12032315, ECO:0000269|PubMed:29880844, ECO:0000269|PubMed:34788109}. |
| Q92918 | MAP4K1 | T165 | psp | Mitogen-activated protein kinase kinase kinase kinase 1 (EC 2.7.11.1) (Hematopoietic progenitor kinase) (MAPK/ERK kinase kinase kinase 1) (MEK kinase kinase 1) (MEKKK 1) | Serine/threonine-protein kinase, which plays a role in the response to environmental stress (PubMed:24362026). Appears to act upstream of the JUN N-terminal pathway (PubMed:8824585). Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:26437443). May play a role in hematopoietic lineage decisions and growth regulation (PubMed:24362026, PubMed:8824585). Together with CLNK, it enhances CD3-triggered activation of T-cells and subsequent IL2 production (By similarity). {ECO:0000250|UniProtKB:P70218, ECO:0000269|PubMed:24362026, ECO:0000269|PubMed:26437443, ECO:0000269|PubMed:8824585}. |
| Q96PY6 | NEK1 | T156 | psp | Serine/threonine-protein kinase Nek1 (EC 2.7.11.1) (Never in mitosis A-related kinase 1) (NimA-related protein kinase 1) (Renal carcinoma antigen NY-REN-55) | Phosphorylates serines and threonines, but also appears to possess tyrosine kinase activity (PubMed:20230784). Involved in DNA damage checkpoint control and for proper DNA damage repair (PubMed:20230784). In response to injury that includes DNA damage, NEK1 phosphorylates VDAC1 to limit mitochondrial cell death (PubMed:20230784). May be implicated in the control of meiosis (By similarity). Involved in cilium assembly (PubMed:21211617). {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:20230784, ECO:0000269|PubMed:21211617}. |
| Q99759 | MAP3K3 | S520 | psp | Mitogen-activated protein kinase kinase kinase 3 (EC 2.7.11.25) (MAPK/ERK kinase kinase 3) (MEK kinase 3) (MEKK 3) | Component of a protein kinase signal transduction cascade. Mediates activation of the NF-kappa-B, AP1 and DDIT3 transcriptional regulators. {ECO:0000269|PubMed:12912994, ECO:0000269|PubMed:14661019, ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:33729480, ECO:0000269|PubMed:33891857, ECO:0000269|PubMed:9006902}. |
| Q9BQE3 | TUBA1C | T73 | ochoa | Tubulin alpha-1C chain (EC 3.6.5.-) (Alpha-tubulin 6) (Tubulin alpha-6 chain) [Cleaved into: Detyrosinated tubulin alpha-1C chain] | Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin. |
| Q9H2G2 | SLK | T183 | ochoa|psp | STE20-like serine/threonine-protein kinase (STE20-like kinase) (hSLK) (EC 2.7.11.1) (CTCL tumor antigen se20-9) (STE20-related serine/threonine-protein kinase) (STE20-related kinase) (Serine/threonine-protein kinase 2) | Mediates apoptosis and actin stress fiber dissolution. {ECO:0000250}. |
| Q9P289 | STK26 | T172 | ochoa | Serine/threonine-protein kinase 26 (EC 2.7.11.1) (MST3 and SOK1-related kinase) (Mammalian STE20-like protein kinase 4) (MST-4) (STE20-like kinase MST4) (Serine/threonine-protein kinase MASK) | Serine/threonine-protein kinase that acts as a mediator of cell growth (PubMed:11641781, PubMed:17360971). Modulates apoptosis (PubMed:11641781, PubMed:17360971). In association with STK24 negatively regulates Golgi reorientation in polarized cell migration upon RHO activation (PubMed:27807006). Phosphorylates ATG4B at 'Ser-383', thereby increasing autophagic flux (PubMed:29232556). Part of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. STRIPAK complexes have critical roles in protein (de)phosphorylation and are regulators of multiple signaling pathways including Hippo, MAPK, nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are involved in a variety of biological processes such as cell growth, differentiation, apoptosis, metabolism and immune regulation (PubMed:18782753). {ECO:0000269|PubMed:11641781, ECO:0000269|PubMed:17360971, ECO:0000269|PubMed:18782753, ECO:0000269|PubMed:27807006, ECO:0000269|PubMed:29232556}. |
| Q9UKE5 | TNIK | T181 | ochoa | TRAF2 and NCK-interacting protein kinase (EC 2.7.11.1) | Serine/threonine kinase that acts as an essential activator of the Wnt signaling pathway. Recruited to promoters of Wnt target genes and required to activate their expression. May act by phosphorylating TCF4/TCF7L2. Appears to act upstream of the JUN N-terminal pathway. May play a role in the response to environmental stress. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. More generally, it may play a role in cytoskeletal rearrangements and regulate cell spreading. Phosphorylates SMAD1 on Thr-322. Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:26437443). {ECO:0000269|PubMed:10521462, ECO:0000269|PubMed:15342639, ECO:0000269|PubMed:19061864, ECO:0000269|PubMed:19816403, ECO:0000269|PubMed:20159449, ECO:0000269|PubMed:21690388, ECO:0000269|PubMed:26437443}. |
| Q9UM73 | ALK | Y1282 | psp | ALK tyrosine kinase receptor (EC 2.7.10.1) (Anaplastic lymphoma kinase) (CD antigen CD246) | Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response (PubMed:30061385, PubMed:33411331, PubMed:34646012, PubMed:34819673). In contrast, ALKAL1 is not a potent physiological ligand for ALK (PubMed:34646012). Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway (PubMed:34819673). Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif (PubMed:15226403, PubMed:16878150). Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 (PubMed:15226403, PubMed:16878150). ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) (PubMed:11278720, PubMed:11809760, PubMed:12107166, PubMed:12122009). PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation (PubMed:11278720, PubMed:11809760, PubMed:12107166). MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction (PubMed:12122009). Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase (PubMed:15226403, PubMed:16878150). Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK (PubMed:15226403, PubMed:16878150). {ECO:0000250|UniProtKB:P97793, ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:11278720, ECO:0000269|PubMed:11387242, ECO:0000269|PubMed:11809760, ECO:0000269|PubMed:12107166, ECO:0000269|PubMed:12122009, ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:17274988, ECO:0000269|PubMed:30061385, ECO:0000269|PubMed:33411331, ECO:0000269|PubMed:34646012, ECO:0000269|PubMed:34819673}. |
| Q9Y2U5 | MAP3K2 | S514 | ochoa | Mitogen-activated protein kinase kinase kinase 2 (EC 2.7.11.25) (MAPK/ERK kinase kinase 2) (MEK kinase 2) (MEKK 2) | Component of a protein kinase signal transduction cascade. Regulates the JNK and ERK5 pathways by phosphorylating and activating MAP2K5 and MAP2K7 (By similarity). Plays a role in caveolae kiss-and-run dynamics. {ECO:0000250, ECO:0000269|PubMed:10713157, ECO:0000269|PubMed:16001074}. |
| Q9Y6E0 | STK24 | T184 | ochoa | Serine/threonine-protein kinase 24 (EC 2.7.11.1) (Mammalian STE20-like protein kinase 3) (MST-3) (STE20-like kinase MST3) [Cleaved into: Serine/threonine-protein kinase 24 36 kDa subunit (Mammalian STE20-like protein kinase 3 N-terminal) (MST3/N); Serine/threonine-protein kinase 24 12 kDa subunit (Mammalian STE20-like protein kinase 3 C-terminal) (MST3/C)] | Serine/threonine-protein kinase that acts on both serine and threonine residues and promotes apoptosis in response to stress stimuli and caspase activation. Mediates oxidative-stress-induced cell death by modulating phosphorylation of JNK1-JNK2 (MAPK8 and MAPK9), p38 (MAPK11, MAPK12, MAPK13 and MAPK14) during oxidative stress. Plays a role in a staurosporine-induced caspase-independent apoptotic pathway by regulating the nuclear translocation of AIFM1 and ENDOG and the DNase activity associated with ENDOG. Phosphorylates STK38L on 'Thr-442' and stimulates its kinase activity. In association with STK26 negatively regulates Golgi reorientation in polarized cell migration upon RHO activation (PubMed:27807006). Also regulates cellular migration with alteration of PTPN12 activity and PXN phosphorylation: phosphorylates PTPN12 and inhibits its activity and may regulate PXN phosphorylation through PTPN12. May act as a key regulator of axon regeneration in the optic nerve and radial nerve. Part of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. STRIPAK complexes have critical roles in protein (de)phosphorylation and are regulators of multiple signaling pathways including Hippo, MAPK, nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are involved in a variety of biological processes such as cell growth, differentiation, apoptosis, metabolism and immune regulation (PubMed:18782753). {ECO:0000269|PubMed:16314523, ECO:0000269|PubMed:17046825, ECO:0000269|PubMed:18782753, ECO:0000269|PubMed:19604147, ECO:0000269|PubMed:19782762, ECO:0000269|PubMed:19855390, ECO:0000269|PubMed:27807006}. |
| O15146 | MUSK | Y755 | Sugiyama | Muscle, skeletal receptor tyrosine-protein kinase (EC 2.7.10.1) (Muscle-specific tyrosine-protein kinase receptor) (MuSK) (Muscle-specific kinase receptor) | Receptor tyrosine kinase which plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between the motor neuron and the skeletal muscle (PubMed:25537362). Recruitment of AGRIN by LRP4 to the MUSK signaling complex induces phosphorylation and activation of MUSK, the kinase of the complex. The activation of MUSK in myotubes regulates the formation of NMJs through the regulation of different processes including the specific expression of genes in subsynaptic nuclei, the reorganization of the actin cytoskeleton and the clustering of the acetylcholine receptors (AChR) in the postsynaptic membrane. May regulate AChR phosphorylation and clustering through activation of ABL1 and Src family kinases which in turn regulate MUSK. DVL1 and PAK1 that form a ternary complex with MUSK are also important for MUSK-dependent regulation of AChR clustering. May positively regulate Rho family GTPases through FNTA. Mediates the phosphorylation of FNTA which promotes prenylation, recruitment to membranes and activation of RAC1 a regulator of the actin cytoskeleton and of gene expression. Other effectors of the MUSK signaling include DNAJA3 which functions downstream of MUSK. May also play a role within the central nervous system by mediating cholinergic responses, synaptic plasticity and memory formation (By similarity). {ECO:0000250, ECO:0000269|PubMed:25537362}. |
| P0DPH7 | TUBA3C | T73 | Sugiyama | Tubulin alpha-3C chain (EC 3.6.5.-) (Alpha-tubulin 2) (Alpha-tubulin 3C) (Tubulin alpha-2 chain) [Cleaved into: Detyrosinated tubulin alpha-3C chain] | Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin. |
| Q6PEY2 | TUBA3E | T73 | Sugiyama | Tubulin alpha-3E chain (EC 3.6.5.-) (Alpha-tubulin 3E) [Cleaved into: Detyrosinated tubulin alpha-3E chain] | Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin. |
| P07949 | RET | S904 | Sugiyama | Proto-oncogene tyrosine-protein kinase receptor Ret (EC 2.7.10.1) (Cadherin family member 12) (Proto-oncogene c-Ret) [Cleaved into: Soluble RET kinase fragment; Extracellular cell-membrane anchored RET cadherin 120 kDa fragment] | Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, PubMed:28953886, PubMed:31118272). In contrast to most receptor tyrosine kinases, RET requires not only its cognate ligands but also coreceptors, for activation (PubMed:21994944, PubMed:23333276, PubMed:28846097, PubMed:28846099, PubMed:28953886). GDNF ligands (GDNF, NRTN, ARTN, PSPN and GDF15) first bind their corresponding GDNFR coreceptors (GFRA1, GFRA2, GFRA3, GFRA4 and GFRAL, respectively), triggering RET autophosphorylation and activation, leading to activation of downstream signaling pathways, including the MAPK- and AKT-signaling pathways (PubMed:21994944, PubMed:23333276, PubMed:24560924, PubMed:25242331, PubMed:28846097, PubMed:28846099, PubMed:28953886). Acts as a dependence receptor via the GDNF-GFRA1 signaling: in the presence of the ligand GDNF in somatotrophs within pituitary, promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF (PubMed:20616503, PubMed:21994944). Required for the molecular mechanisms orchestration during intestine organogenesis via the ARTN-GFRA3 signaling: involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue (By similarity). Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses (PubMed:28846097, PubMed:28846099, PubMed:28953886). Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner (PubMed:20702524, PubMed:21357690). Also active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage (PubMed:21357690). Triggers the differentiation of rapidly adapting (RA) mechanoreceptors (PubMed:20064382). Involved in the development of the neural crest (By similarity). Regulates nociceptor survival and size (By similarity). Phosphorylates PTK2/FAK1 (PubMed:21454698). {ECO:0000250|UniProtKB:P35546, ECO:0000269|PubMed:20064382, ECO:0000269|PubMed:20616503, ECO:0000269|PubMed:20702524, ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698, ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:28846097, ECO:0000269|PubMed:28846099, ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:31118272}.; FUNCTION: [Isoform 1]: Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. {ECO:0000269|PubMed:28846099}. |
| P14616 | INSRR | Y1145 | Sugiyama | Insulin receptor-related protein (IRR) (EC 2.7.10.1) (IR-related receptor) [Cleaved into: Insulin receptor-related protein alpha chain; Insulin receptor-related protein beta chain] | Receptor with tyrosine-protein kinase activity. Functions as a pH sensing receptor which is activated by increased extracellular pH. Activates an intracellular signaling pathway that involves IRS1 and AKT1/PKB. {ECO:0000269|PubMed:21641549}. |
| Q04912 | MST1R | S1240 | Sugiyama | Macrophage-stimulating protein receptor (MSP receptor) (EC 2.7.10.1) (CDw136) (Protein-tyrosine kinase 8) (p185-Ron) (CD antigen CD136) [Cleaved into: Macrophage-stimulating protein receptor alpha chain; Macrophage-stimulating protein receptor beta chain] | Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Also plays a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand. {ECO:0000269|PubMed:18836480, ECO:0000269|PubMed:7939629, ECO:0000269|PubMed:9764835}. |
Download
| reactome_id | name | p | -log10_p |
|---|---|---|---|
| R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | 1.110223e-16 | 15.955 |
| R-HSA-162582 | Signal Transduction | 2.220446e-16 | 15.654 |
| R-HSA-1226099 | Signaling by FGFR in disease | 1.554312e-15 | 14.808 |
| R-HSA-5663202 | Diseases of signal transduction by growth factor receptors and second messengers | 1.421085e-14 | 13.847 |
| R-HSA-5684996 | MAPK1/MAPK3 signaling | 1.110223e-14 | 13.955 |
| R-HSA-5683057 | MAPK family signaling cascades | 1.254552e-14 | 13.902 |
| R-HSA-5673001 | RAF/MAP kinase cascade | 1.028067e-13 | 12.988 |
| R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | 7.893686e-13 | 12.103 |
| R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 9.423573e-13 | 12.026 |
| R-HSA-199418 | Negative regulation of the PI3K/AKT network | 1.902478e-12 | 11.721 |
| R-HSA-2428928 | IRS-related events triggered by IGF1R | 7.797984e-12 | 11.108 |
| R-HSA-2428924 | IGF1R signaling cascade | 1.177591e-11 | 10.929 |
| R-HSA-74751 | Insulin receptor signalling cascade | 1.177591e-11 | 10.929 |
| R-HSA-2219528 | PI3K/AKT Signaling in Cancer | 1.218703e-11 | 10.914 |
| R-HSA-2404192 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 1.345735e-11 | 10.871 |
| R-HSA-1643685 | Disease | 3.940048e-11 | 10.404 |
| R-HSA-109704 | PI3K Cascade | 5.003031e-11 | 10.301 |
| R-HSA-112399 | IRS-mediated signalling | 1.352073e-10 | 9.869 |
| R-HSA-422475 | Axon guidance | 2.496828e-10 | 9.603 |
| R-HSA-74752 | Signaling by Insulin receptor | 3.353291e-10 | 9.475 |
| R-HSA-9675108 | Nervous system development | 7.106672e-10 | 9.148 |
| R-HSA-5210891 | Uptake and function of anthrax toxins | 3.428923e-09 | 8.465 |
| R-HSA-190236 | Signaling by FGFR | 1.164413e-08 | 7.934 |
| R-HSA-1257604 | PIP3 activates AKT signaling | 2.155156e-08 | 7.667 |
| R-HSA-373760 | L1CAM interactions | 5.175315e-08 | 7.286 |
| R-HSA-9006925 | Intracellular signaling by second messengers | 1.067074e-07 | 6.972 |
| R-HSA-1839126 | FGFR2 mutant receptor activation | 1.742573e-07 | 6.759 |
| R-HSA-190840 | Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | 1.795589e-07 | 6.746 |
| R-HSA-190872 | Transport of connexons to the plasma membrane | 2.232790e-07 | 6.651 |
| R-HSA-2559580 | Oxidative Stress Induced Senescence | 2.505713e-07 | 6.601 |
| R-HSA-8851708 | Signaling by FGFR2 IIIa TM | 2.750301e-07 | 6.561 |
| R-HSA-389977 | Post-chaperonin tubulin folding pathway | 3.358455e-07 | 6.474 |
| R-HSA-112409 | RAF-independent MAPK1/3 activation | 5.842207e-07 | 6.233 |
| R-HSA-112411 | MAPK1 (ERK2) activation | 7.157908e-07 | 6.145 |
| R-HSA-389960 | Formation of tubulin folding intermediates by CCT/TriC | 8.177589e-07 | 6.087 |
| R-HSA-110056 | MAPK3 (ERK1) activation | 9.817558e-07 | 6.008 |
| R-HSA-5655253 | Signaling by FGFR2 in disease | 9.822590e-07 | 6.008 |
| R-HSA-5339562 | Uptake and actions of bacterial toxins | 1.193266e-06 | 5.923 |
| R-HSA-9619483 | Activation of AMPK downstream of NMDARs | 1.502726e-06 | 5.823 |
| R-HSA-389958 | Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 2.263836e-06 | 5.645 |
| R-HSA-9668328 | Sealing of the nuclear envelope (NE) by ESCRT-III | 2.920076e-06 | 5.535 |
| R-HSA-190861 | Gap junction assembly | 3.717284e-06 | 5.430 |
| R-HSA-5663205 | Infectious disease | 4.085584e-06 | 5.389 |
| R-HSA-170670 | Adenylate cyclase inhibitory pathway | 4.367802e-06 | 5.360 |
| R-HSA-169893 | Prolonged ERK activation events | 5.339973e-06 | 5.272 |
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 6.018693e-06 | 5.220 |
| R-HSA-9646399 | Aggrephagy | 7.169771e-06 | 5.144 |
| R-HSA-9609736 | Assembly and cell surface presentation of NMDA receptors | 8.754556e-06 | 5.058 |
| R-HSA-3928664 | Ephrin signaling | 9.222392e-06 | 5.035 |
| R-HSA-9833482 | PKR-mediated signaling | 1.049945e-05 | 4.979 |
| R-HSA-190828 | Gap junction trafficking | 1.163130e-05 | 4.934 |
| R-HSA-5654221 | Phospholipase C-mediated cascade; FGFR2 | 1.276543e-05 | 4.894 |
| R-HSA-8955332 | Carboxyterminal post-translational modifications of tubulin | 1.519791e-05 | 4.818 |
| R-HSA-190241 | FGFR2 ligand binding and activation | 1.487102e-05 | 4.828 |
| R-HSA-392170 | ADP signalling through P2Y purinoceptor 12 | 1.487102e-05 | 4.828 |
| R-HSA-437239 | Recycling pathway of L1 | 1.519791e-05 | 4.818 |
| R-HSA-2559583 | Cellular Senescence | 1.578496e-05 | 4.802 |
| R-HSA-9705462 | Inactivation of CSF3 (G-CSF) signaling | 1.722165e-05 | 4.764 |
| R-HSA-157858 | Gap junction trafficking and regulation | 1.801294e-05 | 4.744 |
| R-HSA-8854691 | Interleukin-20 family signaling | 2.272777e-05 | 4.643 |
| R-HSA-187015 | Activation of TRKA receptors | 2.613026e-05 | 4.583 |
| R-HSA-5654695 | PI-3K cascade:FGFR2 | 2.942779e-05 | 4.531 |
| R-HSA-6811436 | COPI-independent Golgi-to-ER retrograde traffic | 2.894922e-05 | 4.538 |
| R-HSA-5654699 | SHC-mediated cascade:FGFR2 | 3.747260e-05 | 4.426 |
| R-HSA-5654700 | FRS-mediated FGFR2 signaling | 4.204822e-05 | 4.376 |
| R-HSA-9009391 | Extra-nuclear estrogen signaling | 4.015378e-05 | 4.396 |
| R-HSA-450294 | MAP kinase activation | 4.445379e-05 | 4.352 |
| R-HSA-983189 | Kinesins | 4.150363e-05 | 4.382 |
| R-HSA-9674555 | Signaling by CSF3 (G-CSF) | 4.701952e-05 | 4.328 |
| R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint | 4.756370e-05 | 4.323 |
| R-HSA-9020956 | Interleukin-27 signaling | 5.672419e-05 | 4.246 |
| R-HSA-1169410 | Antiviral mechanism by IFN-stimulated genes | 5.085302e-05 | 4.294 |
| R-HSA-3371497 | HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of lig... | 6.991800e-05 | 4.155 |
| R-HSA-9020558 | Interleukin-2 signaling | 7.056478e-05 | 4.151 |
| R-HSA-448424 | Interleukin-17 signaling | 7.892971e-05 | 4.103 |
| R-HSA-5620920 | Cargo trafficking to the periciliary membrane | 8.375802e-05 | 4.077 |
| R-HSA-5654727 | Negative regulation of FGFR2 signaling | 8.633588e-05 | 4.064 |
| R-HSA-392518 | Signal amplification | 8.633588e-05 | 4.064 |
| R-HSA-1445148 | Translocation of SLC2A4 (GLUT4) to the plasma membrane | 9.409432e-05 | 4.026 |
| R-HSA-1280215 | Cytokine Signaling in Immune system | 9.456115e-05 | 4.024 |
| R-HSA-5654696 | Downstream signaling of activated FGFR2 | 9.467360e-05 | 4.024 |
| R-HSA-187687 | Signalling to ERKs | 9.467360e-05 | 4.024 |
| R-HSA-2033514 | FGFR3 mutant receptor activation | 1.248388e-04 | 3.904 |
| R-HSA-1839130 | Signaling by activated point mutants of FGFR3 | 1.248388e-04 | 3.904 |
| R-HSA-8984722 | Interleukin-35 Signalling | 1.044952e-04 | 3.981 |
| R-HSA-6788467 | IL-6-type cytokine receptor ligand interactions | 1.248388e-04 | 3.904 |
| R-HSA-1059683 | Interleukin-6 signaling | 1.248388e-04 | 3.904 |
| R-HSA-170968 | Frs2-mediated activation | 1.248388e-04 | 3.904 |
| R-HSA-983231 | Factors involved in megakaryocyte development and platelet production | 1.071104e-04 | 3.970 |
| R-HSA-112315 | Transmission across Chemical Synapses | 1.235649e-04 | 3.908 |
| R-HSA-1266738 | Developmental Biology | 1.283431e-04 | 3.892 |
| R-HSA-109582 | Hemostasis | 1.335233e-04 | 3.874 |
| R-HSA-2995410 | Nuclear Envelope (NE) Reassembly | 1.381727e-04 | 3.860 |
| R-HSA-451927 | Interleukin-2 family signaling | 1.453804e-04 | 3.837 |
| R-HSA-187037 | Signaling by NTRK1 (TRKA) | 1.518062e-04 | 3.819 |
| R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes | 2.162711e-04 | 3.665 |
| R-HSA-3928662 | EPHB-mediated forward signaling | 2.133128e-04 | 3.671 |
| R-HSA-512988 | Interleukin-3, Interleukin-5 and GM-CSF signaling | 1.838769e-04 | 3.735 |
| R-HSA-991365 | Activation of GABAB receptors | 1.838769e-04 | 3.735 |
| R-HSA-977444 | GABA B receptor activation | 1.838769e-04 | 3.735 |
| R-HSA-390466 | Chaperonin-mediated protein folding | 2.062385e-04 | 3.686 |
| R-HSA-9663891 | Selective autophagy | 2.162711e-04 | 3.665 |
| R-HSA-438064 | Post NMDA receptor activation events | 2.062385e-04 | 3.686 |
| R-HSA-9660821 | ADORA2B mediated anti-inflammatory cytokines production | 2.292374e-04 | 3.640 |
| R-HSA-2682334 | EPH-Ephrin signaling | 2.721289e-04 | 3.565 |
| R-HSA-391251 | Protein folding | 2.721289e-04 | 3.565 |
| R-HSA-5620924 | Intraflagellar transport | 2.821442e-04 | 3.550 |
| R-HSA-9634597 | GPER1 signaling | 2.821442e-04 | 3.550 |
| R-HSA-2033519 | Activated point mutants of FGFR2 | 3.018528e-04 | 3.520 |
| R-HSA-166520 | Signaling by NTRKs | 3.358165e-04 | 3.474 |
| R-HSA-6811434 | COPI-dependent Golgi-to-ER retrograde traffic | 3.383222e-04 | 3.471 |
| R-HSA-6807878 | COPI-mediated anterograde transport | 3.383222e-04 | 3.471 |
| R-HSA-975871 | MyD88 cascade initiated on plasma membrane | 3.679598e-04 | 3.434 |
| R-HSA-168176 | Toll Like Receptor 5 (TLR5) Cascade | 3.679598e-04 | 3.434 |
| R-HSA-168142 | Toll Like Receptor 10 (TLR10) Cascade | 3.679598e-04 | 3.434 |
| R-HSA-1839120 | Signaling by FGFR1 amplification mutants | 3.708137e-04 | 3.431 |
| R-HSA-187042 | TRKA activation by NGF | 3.708137e-04 | 3.431 |
| R-HSA-2023837 | Signaling by FGFR2 amplification mutants | 3.708137e-04 | 3.431 |
| R-HSA-445144 | Signal transduction by L1 | 3.845662e-04 | 3.415 |
| R-HSA-913531 | Interferon Signaling | 4.102888e-04 | 3.387 |
| R-HSA-442755 | Activation of NMDA receptors and postsynaptic events | 4.330866e-04 | 3.363 |
| R-HSA-418597 | G alpha (z) signalling events | 4.388773e-04 | 3.358 |
| R-HSA-9652169 | Signaling by MAP2K mutants | 5.320562e-04 | 3.274 |
| R-HSA-912526 | Interleukin receptor SHC signaling | 5.907836e-04 | 3.229 |
| R-HSA-389957 | Prefoldin mediated transfer of substrate to CCT/TriC | 5.907836e-04 | 3.229 |
| R-HSA-977443 | GABA receptor activation | 5.833450e-04 | 3.234 |
| R-HSA-9648025 | EML4 and NUDC in mitotic spindle formation | 5.890422e-04 | 3.230 |
| R-HSA-975138 | TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 5.675388e-04 | 3.246 |
| R-HSA-975155 | MyD88 dependent cascade initiated on endosome | 5.890422e-04 | 3.230 |
| R-HSA-168164 | Toll Like Receptor 3 (TLR3) Cascade | 5.065578e-04 | 3.295 |
| R-HSA-937061 | TRIF (TICAM1)-mediated TLR4 signaling | 6.111518e-04 | 3.214 |
| R-HSA-166166 | MyD88-independent TLR4 cascade | 6.111518e-04 | 3.214 |
| R-HSA-6783589 | Interleukin-6 family signaling | 6.514334e-04 | 3.186 |
| R-HSA-168181 | Toll Like Receptor 7/8 (TLR7/8) Cascade | 6.812275e-04 | 3.167 |
| R-HSA-373755 | Semaphorin interactions | 6.846547e-04 | 3.165 |
| R-HSA-168138 | Toll Like Receptor 9 (TLR9) Cascade | 7.571564e-04 | 3.121 |
| R-HSA-112040 | G-protein mediated events | 8.383358e-04 | 3.077 |
| R-HSA-5655332 | Signaling by FGFR3 in disease | 8.567733e-04 | 3.067 |
| R-HSA-449147 | Signaling by Interleukins | 8.812058e-04 | 3.055 |
| R-HSA-166058 | MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 8.975393e-04 | 3.047 |
| R-HSA-168188 | Toll Like Receptor TLR6:TLR2 Cascade | 8.975393e-04 | 3.047 |
| R-HSA-187024 | NGF-independant TRKA activation | 9.391076e-04 | 3.027 |
| R-HSA-5674499 | Negative feedback regulation of MAPK pathway | 9.391076e-04 | 3.027 |
| R-HSA-2500257 | Resolution of Sister Chromatid Cohesion | 9.588024e-04 | 3.018 |
| R-HSA-168179 | Toll Like Receptor TLR1:TLR2 Cascade | 9.905754e-04 | 3.004 |
| R-HSA-181438 | Toll Like Receptor 2 (TLR2) Cascade | 9.905754e-04 | 3.004 |
| R-HSA-2132295 | MHC class II antigen presentation | 1.023125e-03 | 2.990 |
| R-HSA-111465 | Apoptotic cleavage of cellular proteins | 1.282466e-03 | 2.892 |
| R-HSA-1839124 | FGFR1 mutant receptor activation | 1.380907e-03 | 2.860 |
| R-HSA-8856688 | Golgi-to-ER retrograde transport | 1.435847e-03 | 2.843 |
| R-HSA-9658195 | Leishmania infection | 1.443497e-03 | 2.841 |
| R-HSA-9824443 | Parasitic Infection Pathways | 1.443497e-03 | 2.841 |
| R-HSA-428890 | Role of ABL in ROBO-SLIT signaling | 1.456862e-03 | 2.837 |
| R-HSA-9732724 | IFNG signaling activates MAPKs | 1.456862e-03 | 2.837 |
| R-HSA-5654738 | Signaling by FGFR2 | 1.504943e-03 | 2.822 |
| R-HSA-112316 | Neuronal System | 1.564190e-03 | 2.806 |
| R-HSA-5673000 | RAF activation | 1.591747e-03 | 2.798 |
| R-HSA-8985947 | Interleukin-9 signaling | 1.756492e-03 | 2.755 |
| R-HSA-9020933 | Interleukin-23 signaling | 1.756492e-03 | 2.755 |
| R-HSA-8953897 | Cellular responses to stimuli | 1.774122e-03 | 2.751 |
| R-HSA-1632852 | Macroautophagy | 1.907405e-03 | 2.720 |
| R-HSA-9824439 | Bacterial Infection Pathways | 2.030625e-03 | 2.692 |
| R-HSA-9020958 | Interleukin-21 signaling | 2.082890e-03 | 2.681 |
| R-HSA-201556 | Signaling by ALK | 2.203855e-03 | 2.657 |
| R-HSA-199977 | ER to Golgi Anterograde Transport | 2.298997e-03 | 2.638 |
| R-HSA-1839122 | Signaling by activated point mutants of FGFR1 | 3.219729e-03 | 2.492 |
| R-HSA-9656223 | Signaling by RAF1 mutants | 2.632296e-03 | 2.580 |
| R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF | 3.454067e-03 | 2.462 |
| R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants | 3.454067e-03 | 2.462 |
| R-HSA-9649948 | Signaling downstream of RAS mutants | 3.454067e-03 | 2.462 |
| R-HSA-190377 | FGFR2b ligand binding and activation | 2.814802e-03 | 2.551 |
| R-HSA-5655302 | Signaling by FGFR1 in disease | 2.632296e-03 | 2.580 |
| R-HSA-6802949 | Signaling by RAS mutants | 3.454067e-03 | 2.462 |
| R-HSA-9679191 | Potential therapeutics for SARS | 2.483589e-03 | 2.605 |
| R-HSA-8939211 | ESR-mediated signaling | 3.106379e-03 | 2.508 |
| R-HSA-75153 | Apoptotic execution phase | 3.454067e-03 | 2.462 |
| R-HSA-166016 | Toll Like Receptor 4 (TLR4) Cascade | 2.359376e-03 | 2.627 |
| R-HSA-9612973 | Autophagy | 2.884787e-03 | 2.540 |
| R-HSA-5610787 | Hedgehog 'off' state | 3.461505e-03 | 2.461 |
| R-HSA-2467813 | Separation of Sister Chromatids | 3.490173e-03 | 2.457 |
| R-HSA-9020702 | Interleukin-1 signaling | 3.573049e-03 | 2.447 |
| R-HSA-3928665 | EPH-ephrin mediated repulsion of cells | 3.635126e-03 | 2.439 |
| R-HSA-8983432 | Interleukin-15 signaling | 3.650248e-03 | 2.438 |
| R-HSA-877312 | Regulation of IFNG signaling | 3.650248e-03 | 2.438 |
| R-HSA-111885 | Opioid Signalling | 3.922304e-03 | 2.406 |
| R-HSA-190375 | FGFR2c ligand binding and activation | 4.106071e-03 | 2.387 |
| R-HSA-9664433 | Leishmania parasite growth and survival | 4.369342e-03 | 2.360 |
| R-HSA-9662851 | Anti-inflammatory response favouring Leishmania parasite infection | 4.369342e-03 | 2.360 |
| R-HSA-9700206 | Signaling by ALK in cancer | 4.423021e-03 | 2.354 |
| R-HSA-9725370 | Signaling by ALK fusions and activated point mutants | 4.423021e-03 | 2.354 |
| R-HSA-5654227 | Phospholipase C-mediated cascade; FGFR3 | 4.586914e-03 | 2.338 |
| R-HSA-5684264 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | 4.586914e-03 | 2.338 |
| R-HSA-2262752 | Cellular responses to stress | 4.637385e-03 | 2.334 |
| R-HSA-190239 | FGFR3 ligand binding and activation | 5.092491e-03 | 2.293 |
| R-HSA-399954 | Sema3A PAK dependent Axon repulsion | 5.092491e-03 | 2.293 |
| R-HSA-9700649 | Drug resistance of ALK mutants | 5.511846e-03 | 2.259 |
| R-HSA-9717301 | NVP-TAE684-resistant ALK mutants | 5.511846e-03 | 2.259 |
| R-HSA-9717316 | alectinib-resistant ALK mutants | 5.511846e-03 | 2.259 |
| R-HSA-9717319 | brigatinib-resistant ALK mutants | 5.511846e-03 | 2.259 |
| R-HSA-9717326 | crizotinib-resistant ALK mutants | 5.511846e-03 | 2.259 |
| R-HSA-9717264 | ASP-3026-resistant ALK mutants | 5.511846e-03 | 2.259 |
| R-HSA-9717323 | ceritinib-resistant ALK mutants | 5.511846e-03 | 2.259 |
| R-HSA-9717329 | lorlatinib-resistant ALK mutants | 5.511846e-03 | 2.259 |
| R-HSA-69275 | G2/M Transition | 5.735261e-03 | 2.241 |
| R-HSA-76002 | Platelet activation, signaling and aggregation | 5.926132e-03 | 2.227 |
| R-HSA-453274 | Mitotic G2-G2/M phases | 5.969347e-03 | 2.224 |
| R-HSA-8866910 | TFAP2 (AP-2) family regulates transcription of growth factors and their receptor... | 6.176731e-03 | 2.209 |
| R-HSA-5617833 | Cilium Assembly | 6.210098e-03 | 2.207 |
| R-HSA-168898 | Toll-like Receptor Cascades | 6.333004e-03 | 2.198 |
| R-HSA-68877 | Mitotic Prometaphase | 6.583938e-03 | 2.182 |
| R-HSA-5654219 | Phospholipase C-mediated cascade: FGFR1 | 6.754839e-03 | 2.170 |
| R-HSA-2028269 | Signaling by Hippo | 6.754839e-03 | 2.170 |
| R-HSA-9609690 | HCMV Early Events | 6.973325e-03 | 2.157 |
| R-HSA-190242 | FGFR1 ligand binding and activation | 7.356571e-03 | 2.133 |
| R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic | 7.517252e-03 | 2.124 |
| R-HSA-9734091 | Drug-mediated inhibition of MET activation | 1.099365e-02 | 1.959 |
| R-HSA-5654704 | SHC-mediated cascade:FGFR3 | 9.300808e-03 | 2.031 |
| R-HSA-5654706 | FRS-mediated FGFR3 signaling | 9.994343e-03 | 2.000 |
| R-HSA-9938206 | Developmental Lineage of Mammary Stem Cells | 1.071016e-02 | 1.970 |
| R-HSA-5654688 | SHC-mediated cascade:FGFR1 | 1.220763e-02 | 1.913 |
| R-HSA-5654693 | FRS-mediated FGFR1 signaling | 1.298875e-02 | 1.886 |
| R-HSA-8874081 | MET activates PTK2 signaling | 1.379113e-02 | 1.860 |
| R-HSA-6802952 | Signaling by BRAF and RAF1 fusions | 7.916679e-03 | 2.101 |
| R-HSA-5654710 | PI-3K cascade:FGFR3 | 7.981656e-03 | 2.098 |
| R-HSA-5654689 | PI-3K cascade:FGFR1 | 1.071016e-02 | 1.970 |
| R-HSA-912694 | Regulation of IFNA/IFNB signaling | 1.071016e-02 | 1.970 |
| R-HSA-400685 | Sema4D in semaphorin signaling | 1.298875e-02 | 1.886 |
| R-HSA-450321 | JNK (c-Jun kinases) phosphorylation and activation mediated by activated human ... | 9.300808e-03 | 2.031 |
| R-HSA-6802957 | Oncogenic MAPK signaling | 1.513200e-02 | 1.820 |
| R-HSA-450302 | activated TAK1 mediates p38 MAPK activation | 9.994343e-03 | 2.000 |
| R-HSA-400042 | Adrenaline,noradrenaline inhibits insulin secretion | 1.379113e-02 | 1.860 |
| R-HSA-1266695 | Interleukin-7 signaling | 1.298875e-02 | 1.886 |
| R-HSA-525793 | Myogenesis | 1.379113e-02 | 1.860 |
| R-HSA-9020591 | Interleukin-12 signaling | 1.155105e-02 | 1.937 |
| R-HSA-9830364 | Formation of the nephric duct | 1.298875e-02 | 1.886 |
| R-HSA-9825892 | Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 9.994343e-03 | 2.000 |
| R-HSA-68882 | Mitotic Anaphase | 1.016121e-02 | 1.993 |
| R-HSA-2555396 | Mitotic Metaphase and Anaphase | 1.033424e-02 | 1.986 |
| R-HSA-9022699 | MECP2 regulates neuronal receptors and channels | 1.379113e-02 | 1.860 |
| R-HSA-449836 | Other interleukin signaling | 7.981656e-03 | 2.098 |
| R-HSA-948021 | Transport to the Golgi and subsequent modification | 7.800035e-03 | 2.108 |
| R-HSA-446652 | Interleukin-1 family signaling | 1.491695e-02 | 1.826 |
| R-HSA-5358351 | Signaling by Hedgehog | 1.096703e-02 | 1.960 |
| R-HSA-5654732 | Negative regulation of FGFR3 signaling | 1.545866e-02 | 1.811 |
| R-HSA-5654708 | Downstream signaling of activated FGFR3 | 1.632330e-02 | 1.787 |
| R-HSA-9927432 | Developmental Lineage of Mammary Gland Myoepithelial Cells | 1.632330e-02 | 1.787 |
| R-HSA-1839128 | FGFR4 mutant receptor activation | 1.644558e-02 | 1.784 |
| R-HSA-2033515 | t(4;14) translocations of FGFR3 | 1.644558e-02 | 1.784 |
| R-HSA-8853333 | Signaling by FGFR2 fusions | 1.644558e-02 | 1.784 |
| R-HSA-8853334 | Signaling by FGFR3 fusions in cancer | 1.644558e-02 | 1.784 |
| R-HSA-447115 | Interleukin-12 family signaling | 1.644965e-02 | 1.784 |
| R-HSA-9609646 | HCMV Infection | 1.723753e-02 | 1.764 |
| R-HSA-9833109 | Evasion by RSV of host interferon responses | 1.811311e-02 | 1.742 |
| R-HSA-9006931 | Signaling by Nuclear Receptors | 1.969536e-02 | 1.706 |
| R-HSA-354192 | Integrin signaling | 1.998202e-02 | 1.699 |
| R-HSA-5654726 | Negative regulation of FGFR1 signaling | 1.998202e-02 | 1.699 |
| R-HSA-418555 | G alpha (s) signalling events | 2.143705e-02 | 1.669 |
| R-HSA-9665230 | Drug resistance in ERBB2 KD mutants | 2.186778e-02 | 1.660 |
| R-HSA-9024909 | BDNF activates NTRK2 (TRKB) signaling | 2.186778e-02 | 1.660 |
| R-HSA-9652282 | Drug-mediated inhibition of ERBB2 signaling | 2.186778e-02 | 1.660 |
| R-HSA-9025046 | NTF3 activates NTRK2 (TRKB) signaling | 2.186778e-02 | 1.660 |
| R-HSA-9026357 | NTF4 activates NTRK2 (TRKB) signaling | 2.186778e-02 | 1.660 |
| R-HSA-9665233 | Resistance of ERBB2 KD mutants to trastuzumab | 2.186778e-02 | 1.660 |
| R-HSA-9665249 | Resistance of ERBB2 KD mutants to afatinib | 2.186778e-02 | 1.660 |
| R-HSA-9665251 | Resistance of ERBB2 KD mutants to lapatinib | 2.186778e-02 | 1.660 |
| R-HSA-9665245 | Resistance of ERBB2 KD mutants to tesevatinib | 2.186778e-02 | 1.660 |
| R-HSA-9665250 | Resistance of ERBB2 KD mutants to AEE788 | 2.186778e-02 | 1.660 |
| R-HSA-9665244 | Resistance of ERBB2 KD mutants to sapitinib | 2.186778e-02 | 1.660 |
| R-HSA-9665247 | Resistance of ERBB2 KD mutants to osimertinib | 2.186778e-02 | 1.660 |
| R-HSA-9665246 | Resistance of ERBB2 KD mutants to neratinib | 2.186778e-02 | 1.660 |
| R-HSA-9665737 | Drug resistance in ERBB2 TMD/JMD mutants | 2.186778e-02 | 1.660 |
| R-HSA-198765 | Signalling to ERK5 | 2.186778e-02 | 1.660 |
| R-HSA-9768919 | NPAS4 regulates expression of target genes | 2.192809e-02 | 1.659 |
| R-HSA-5654687 | Downstream signaling of activated FGFR1 | 2.292948e-02 | 1.640 |
| R-HSA-9860927 | Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZ... | 2.292948e-02 | 1.640 |
| R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants | 2.498780e-02 | 1.602 |
| R-HSA-8875878 | MET promotes cell motility | 2.604427e-02 | 1.584 |
| R-HSA-167021 | PLC-gamma1 signalling | 2.726043e-02 | 1.564 |
| R-HSA-8853336 | Signaling by plasma membrane FGFR1 fusions | 2.726043e-02 | 1.564 |
| R-HSA-8875513 | MET interacts with TNS proteins | 2.726043e-02 | 1.564 |
| R-HSA-8865999 | MET activates PTPN11 | 2.726043e-02 | 1.564 |
| R-HSA-198745 | Signalling to STAT3 | 2.726043e-02 | 1.564 |
| R-HSA-8875791 | MET activates STAT3 | 2.726043e-02 | 1.564 |
| R-HSA-9607240 | FLT3 Signaling | 2.932021e-02 | 1.533 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 2.991511e-02 | 1.524 |
| R-HSA-5674135 | MAP2K and MAPK activation | 3.044696e-02 | 1.516 |
| R-HSA-5675221 | Negative regulation of MAPK pathway | 3.044696e-02 | 1.516 |
| R-HSA-9927418 | Developmental Lineage of Mammary Gland Luminal Epithelial Cells | 3.159072e-02 | 1.500 |
| R-HSA-418594 | G alpha (i) signalling events | 3.159380e-02 | 1.500 |
| R-HSA-2871796 | FCERI mediated MAPK activation | 3.178008e-02 | 1.498 |
| R-HSA-9026527 | Activated NTRK2 signals through PLCG1 | 3.262369e-02 | 1.486 |
| R-HSA-1307965 | betaKlotho-mediated ligand binding | 3.262369e-02 | 1.486 |
| R-HSA-1251932 | PLCG1 events in ERBB2 signaling | 3.262369e-02 | 1.486 |
| R-HSA-1306955 | GRB7 events in ERBB2 signaling | 3.262369e-02 | 1.486 |
| R-HSA-9851151 | MDK and PTN in ALK signaling | 3.262369e-02 | 1.486 |
| R-HSA-9706374 | FLT3 signaling through SRC family kinases | 3.262369e-02 | 1.486 |
| R-HSA-1433557 | Signaling by SCF-KIT | 3.275129e-02 | 1.485 |
| R-HSA-69236 | G1 Phase | 3.392843e-02 | 1.469 |
| R-HSA-69231 | Cyclin D associated events in G1 | 3.392843e-02 | 1.469 |
| R-HSA-8864260 | Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 3.392843e-02 | 1.469 |
| R-HSA-4420097 | VEGFA-VEGFR2 Pathway | 3.509308e-02 | 1.455 |
| R-HSA-5654741 | Signaling by FGFR3 | 3.512195e-02 | 1.454 |
| R-HSA-76009 | Platelet Aggregation (Plug Formation) | 3.512195e-02 | 1.454 |
| R-HSA-74713 | IRS activation | 3.795770e-02 | 1.421 |
| R-HSA-190374 | FGFR1c and Klotho ligand binding and activation | 3.795770e-02 | 1.421 |
| R-HSA-9032759 | NTRK2 activates RAC1 | 3.795770e-02 | 1.421 |
| R-HSA-9725371 | Nuclear events stimulated by ALK signaling in cancer | 3.879863e-02 | 1.411 |
| R-HSA-1852241 | Organelle biogenesis and maintenance | 4.061576e-02 | 1.391 |
| R-HSA-194138 | Signaling by VEGF | 4.298465e-02 | 1.367 |
| R-HSA-187706 | Signalling to p38 via RIT and RIN | 4.326262e-02 | 1.364 |
| R-HSA-8852405 | Signaling by MST1 | 4.326262e-02 | 1.364 |
| R-HSA-9758919 | Epithelial-Mesenchymal Transition (EMT) during gastrulation | 4.326262e-02 | 1.364 |
| R-HSA-9634815 | Transcriptional Regulation by NPAS4 | 4.391740e-02 | 1.357 |
| R-HSA-69278 | Cell Cycle, Mitotic | 4.415270e-02 | 1.355 |
| R-HSA-9027283 | Erythropoietin activates STAT5 | 4.853863e-02 | 1.314 |
| R-HSA-6806942 | MET Receptor Activation | 4.853863e-02 | 1.314 |
| R-HSA-5654736 | Signaling by FGFR1 | 4.927183e-02 | 1.307 |
| R-HSA-9824446 | Viral Infection Pathways | 5.172055e-02 | 1.286 |
| R-HSA-9032845 | Activated NTRK2 signals through CDK5 | 5.378586e-02 | 1.269 |
| R-HSA-8851907 | MET activates PI3K/AKT signaling | 5.378586e-02 | 1.269 |
| R-HSA-190371 | FGFR3b ligand binding and activation | 5.378586e-02 | 1.269 |
| R-HSA-9820952 | Respiratory Syncytial Virus Infection Pathway | 5.419958e-02 | 1.266 |
| R-HSA-9664417 | Leishmania phagocytosis | 5.676879e-02 | 1.246 |
| R-HSA-9664407 | Parasite infection | 5.676879e-02 | 1.246 |
| R-HSA-9664422 | FCGR3A-mediated phagocytosis | 5.676879e-02 | 1.246 |
| R-HSA-2029482 | Regulation of actin dynamics for phagocytic cup formation | 5.763795e-02 | 1.239 |
| R-HSA-375165 | NCAM signaling for neurite out-growth | 5.771807e-02 | 1.239 |
| R-HSA-9032500 | Activated NTRK2 signals through FYN | 5.900448e-02 | 1.229 |
| R-HSA-9028335 | Activated NTRK2 signals through PI3K | 5.900448e-02 | 1.229 |
| R-HSA-8875656 | MET receptor recycling | 5.900448e-02 | 1.229 |
| R-HSA-190370 | FGFR1b ligand binding and activation | 5.900448e-02 | 1.229 |
| R-HSA-170984 | ARMS-mediated activation | 6.419464e-02 | 1.193 |
| R-HSA-9700645 | ALK mutants bind TKIs | 6.419464e-02 | 1.193 |
| R-HSA-9830369 | Kidney development | 6.511100e-02 | 1.186 |
| R-HSA-8875555 | MET activates RAP1 and RAC1 | 6.935649e-02 | 1.159 |
| R-HSA-9027277 | Erythropoietin activates Phospholipase C gamma (PLCG) | 6.935649e-02 | 1.159 |
| R-HSA-198203 | PI3K/AKT activation | 6.935649e-02 | 1.159 |
| R-HSA-2586552 | Signaling by Leptin | 6.935649e-02 | 1.159 |
| R-HSA-74749 | Signal attenuation | 6.935649e-02 | 1.159 |
| R-HSA-9924644 | Developmental Lineages of the Mammary Gland | 7.280227e-02 | 1.138 |
| R-HSA-68886 | M Phase | 7.299538e-02 | 1.137 |
| R-HSA-4086398 | Ca2+ pathway | 7.437443e-02 | 1.129 |
| R-HSA-3000171 | Non-integrin membrane-ECM interactions | 7.755131e-02 | 1.110 |
| R-HSA-109581 | Apoptosis | 7.831717e-02 | 1.106 |
| R-HSA-416550 | Sema4D mediated inhibition of cell attachment and migration | 7.959588e-02 | 1.099 |
| R-HSA-9026519 | Activated NTRK2 signals through RAS | 7.959588e-02 | 1.099 |
| R-HSA-168256 | Immune System | 8.189225e-02 | 1.087 |
| R-HSA-6783783 | Interleukin-10 signaling | 8.239560e-02 | 1.084 |
| R-HSA-8851805 | MET activates RAS signaling | 8.467372e-02 | 1.072 |
| R-HSA-9634285 | Constitutive Signaling by Overexpressed ERBB2 | 8.467372e-02 | 1.072 |
| R-HSA-9028731 | Activated NTRK2 signals through FRS2 and FRS3 | 8.467372e-02 | 1.072 |
| R-HSA-9027276 | Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 8.467372e-02 | 1.072 |
| R-HSA-2428933 | SHC-related events triggered by IGF1R | 8.467372e-02 | 1.072 |
| R-HSA-1358803 | Downregulation of ERBB2:ERBB3 signaling | 8.467372e-02 | 1.072 |
| R-HSA-6806834 | Signaling by MET | 8.567590e-02 | 1.067 |
| R-HSA-190322 | FGFR4 ligand binding and activation | 8.972386e-02 | 1.047 |
| R-HSA-190373 | FGFR1c ligand binding and activation | 8.972386e-02 | 1.047 |
| R-HSA-6811555 | PI5P Regulates TP53 Acetylation | 8.972386e-02 | 1.047 |
| R-HSA-2029480 | Fcgamma receptor (FCGR) dependent phagocytosis | 9.186156e-02 | 1.037 |
| R-HSA-5655291 | Signaling by FGFR4 in disease | 9.474645e-02 | 1.023 |
| R-HSA-1170546 | Prolactin receptor signaling | 9.474645e-02 | 1.023 |
| R-HSA-177504 | Retrograde neurotrophin signalling | 9.474645e-02 | 1.023 |
| R-HSA-8847993 | ERBB2 Activates PTK6 Signaling | 9.474645e-02 | 1.023 |
| R-HSA-190372 | FGFR3c ligand binding and activation | 9.474645e-02 | 1.023 |
| R-HSA-399956 | CRMPs in Sema3A signaling | 9.474645e-02 | 1.023 |
| R-HSA-391160 | Signal regulatory protein family interactions | 9.474645e-02 | 1.023 |
| R-HSA-446203 | Asparagine N-linked glycosylation | 9.922026e-02 | 1.003 |
| R-HSA-9027284 | Erythropoietin activates RAS | 9.974164e-02 | 1.001 |
| R-HSA-8875360 | InlB-mediated entry of Listeria monocytogenes into host cell | 9.974164e-02 | 1.001 |
| R-HSA-5654228 | Phospholipase C-mediated cascade; FGFR4 | 9.974164e-02 | 1.001 |
| R-HSA-6785631 | ERBB2 Regulates Cell Motility | 9.974164e-02 | 1.001 |
| R-HSA-418885 | DCC mediated attractive signaling | 9.974164e-02 | 1.001 |
| R-HSA-354194 | GRB2:SOS provides linkage to MAPK signaling for Integrins | 1.047096e-01 | 0.980 |
| R-HSA-2485179 | Activation of the phototransduction cascade | 1.047096e-01 | 0.980 |
| R-HSA-399955 | SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 1.047096e-01 | 0.980 |
| R-HSA-9706369 | Negative regulation of FLT3 | 1.047096e-01 | 0.980 |
| R-HSA-8986944 | Transcriptional Regulation by MECP2 | 1.061374e-01 | 0.974 |
| R-HSA-1640170 | Cell Cycle | 1.088666e-01 | 0.963 |
| R-HSA-1963640 | GRB2 events in ERBB2 signaling | 1.096504e-01 | 0.960 |
| R-HSA-1963642 | PI3K events in ERBB2 signaling | 1.145643e-01 | 0.941 |
| R-HSA-372708 | p130Cas linkage to MAPK signaling for integrins | 1.145643e-01 | 0.941 |
| R-HSA-9665348 | Signaling by ERBB2 ECD mutants | 1.194513e-01 | 0.923 |
| R-HSA-422356 | Regulation of insulin secretion | 1.222555e-01 | 0.913 |
| R-HSA-912631 | Regulation of signaling by CBL | 1.243117e-01 | 0.905 |
| R-HSA-2454202 | Fc epsilon receptor (FCERI) signaling | 1.252220e-01 | 0.902 |
| R-HSA-5357801 | Programmed Cell Death | 1.288974e-01 | 0.890 |
| R-HSA-6807004 | Negative regulation of MET activity | 1.291455e-01 | 0.889 |
| R-HSA-5654720 | PI-3K cascade:FGFR4 | 1.291455e-01 | 0.889 |
| R-HSA-416572 | Sema4D induced cell migration and growth-cone collapse | 1.291455e-01 | 0.889 |
| R-HSA-9860931 | Response of endothelial cells to shear stress | 1.333134e-01 | 0.875 |
| R-HSA-167044 | Signalling to RAS | 1.339530e-01 | 0.873 |
| R-HSA-9931295 | PD-L1(CD274) glycosylation and translocation to plasma membrane | 1.339530e-01 | 0.873 |
| R-HSA-9833110 | RSV-host interactions | 1.351783e-01 | 0.869 |
| R-HSA-5654719 | SHC-mediated cascade:FGFR4 | 1.387342e-01 | 0.858 |
| R-HSA-8876384 | Listeria monocytogenes entry into host cells | 1.387342e-01 | 0.858 |
| R-HSA-9734779 | Developmental Cell Lineages of the Integumentary System | 1.426961e-01 | 0.846 |
| R-HSA-5654712 | FRS-mediated FGFR4 signaling | 1.434893e-01 | 0.843 |
| R-HSA-9670439 | Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT m... | 1.434893e-01 | 0.843 |
| R-HSA-9669938 | Signaling by KIT in disease | 1.434893e-01 | 0.843 |
| R-HSA-982772 | Growth hormone receptor signaling | 1.482185e-01 | 0.829 |
| R-HSA-9830674 | Formation of the ureteric bud | 1.482185e-01 | 0.829 |
| R-HSA-9634638 | Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 1.482185e-01 | 0.829 |
| R-HSA-9665686 | Signaling by ERBB2 TMD/JMD mutants | 1.529218e-01 | 0.816 |
| R-HSA-202430 | Translocation of ZAP-70 to Immunological synapse | 1.529218e-01 | 0.816 |
| R-HSA-9855142 | Cellular responses to mechanical stimuli | 1.541345e-01 | 0.812 |
| R-HSA-909733 | Interferon alpha/beta signaling | 1.599198e-01 | 0.796 |
| R-HSA-9006115 | Signaling by NTRK2 (TRKB) | 1.668783e-01 | 0.778 |
| R-HSA-77387 | Insulin receptor recycling | 1.714797e-01 | 0.766 |
| R-HSA-9638334 | Iron assimilation using enterobactin | 1.714797e-01 | 0.766 |
| R-HSA-8940973 | RUNX2 regulates osteoblast differentiation | 1.714797e-01 | 0.766 |
| R-HSA-9006335 | Signaling by Erythropoietin | 1.760560e-01 | 0.754 |
| R-HSA-9664565 | Signaling by ERBB2 KD Mutants | 1.760560e-01 | 0.754 |
| R-HSA-5654733 | Negative regulation of FGFR4 signaling | 1.760560e-01 | 0.754 |
| R-HSA-1227990 | Signaling by ERBB2 in Cancer | 1.806073e-01 | 0.743 |
| R-HSA-5654716 | Downstream signaling of activated FGFR4 | 1.806073e-01 | 0.743 |
| R-HSA-1250196 | SHC1 events in ERBB2 signaling | 1.806073e-01 | 0.743 |
| R-HSA-8863795 | Downregulation of ERBB2 signaling | 1.806073e-01 | 0.743 |
| R-HSA-2424491 | DAP12 signaling | 1.806073e-01 | 0.743 |
| R-HSA-9820960 | Respiratory syncytial virus (RSV) attachment and entry | 1.851338e-01 | 0.733 |
| R-HSA-5685938 | HDR through Single Strand Annealing (SSA) | 1.941127e-01 | 0.712 |
| R-HSA-6804758 | Regulation of TP53 Activity through Acetylation | 1.941127e-01 | 0.712 |
| R-HSA-168638 | NOD1/2 Signaling Pathway | 2.029937e-01 | 0.693 |
| R-HSA-3858494 | Beta-catenin independent WNT signaling | 2.074199e-01 | 0.683 |
| R-HSA-163685 | Integration of energy metabolism | 2.074199e-01 | 0.683 |
| R-HSA-8853659 | RET signaling | 2.117780e-01 | 0.674 |
| R-HSA-114604 | GPVI-mediated activation cascade | 2.117780e-01 | 0.674 |
| R-HSA-8941326 | RUNX2 regulates bone development | 2.117780e-01 | 0.674 |
| R-HSA-9679506 | SARS-CoV Infections | 2.137731e-01 | 0.670 |
| R-HSA-9705671 | SARS-CoV-2 activates/modulates innate and adaptive immune responses | 2.215658e-01 | 0.654 |
| R-HSA-381771 | Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 2.247752e-01 | 0.648 |
| R-HSA-202433 | Generation of second messenger molecules | 2.290603e-01 | 0.640 |
| R-HSA-453279 | Mitotic G1 phase and G1/S transition | 2.296864e-01 | 0.639 |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated gene... | 2.333220e-01 | 0.632 |
| R-HSA-5218920 | VEGFR2 mediated vascular permeability | 2.333220e-01 | 0.632 |
| R-HSA-1280218 | Adaptive Immune System | 2.367465e-01 | 0.626 |
| R-HSA-9856651 | MITF-M-dependent gene expression | 2.378278e-01 | 0.624 |
| R-HSA-400508 | Incretin synthesis, secretion, and inactivation | 2.417756e-01 | 0.617 |
| R-HSA-5654743 | Signaling by FGFR4 | 2.459678e-01 | 0.609 |
| R-HSA-373752 | Netrin-1 signaling | 2.501371e-01 | 0.602 |
| R-HSA-2172127 | DAP12 interactions | 2.501371e-01 | 0.602 |
| R-HSA-3214858 | RMTs methylate histone arginines | 2.501371e-01 | 0.602 |
| R-HSA-877300 | Interferon gamma signaling | 2.561977e-01 | 0.591 |
| R-HSA-2514859 | Inactivation, recovery and regulation of the phototransduction cascade | 2.584074e-01 | 0.588 |
| R-HSA-9861718 | Regulation of pyruvate metabolism | 2.584074e-01 | 0.588 |
| R-HSA-388396 | GPCR downstream signalling | 2.764005e-01 | 0.558 |
| R-HSA-2514856 | The phototransduction cascade | 2.786906e-01 | 0.555 |
| R-HSA-9662361 | Sensory processing of sound by outer hair cells of the cochlea | 2.984252e-01 | 0.525 |
| R-HSA-5621480 | Dectin-2 family | 3.023075e-01 | 0.520 |
| R-HSA-1474244 | Extracellular matrix organization | 3.068833e-01 | 0.513 |
| R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at... | 3.100086e-01 | 0.509 |
| R-HSA-199991 | Membrane Trafficking | 3.110165e-01 | 0.507 |
| R-HSA-1227986 | Signaling by ERBB2 | 3.138276e-01 | 0.503 |
| R-HSA-9793380 | Formation of paraxial mesoderm | 3.176257e-01 | 0.498 |
| R-HSA-380284 | Loss of proteins required for interphase microtubule organization from the centr... | 3.251596e-01 | 0.488 |
| R-HSA-380259 | Loss of Nlp from mitotic centrosomes | 3.251596e-01 | 0.488 |
| R-HSA-9006927 | Signaling by Non-Receptor Tyrosine Kinases | 3.251596e-01 | 0.488 |
| R-HSA-8848021 | Signaling by PTK6 | 3.251596e-01 | 0.488 |
| R-HSA-168643 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signali... | 3.288956e-01 | 0.483 |
| R-HSA-168249 | Innate Immune System | 3.293366e-01 | 0.482 |
| R-HSA-8854518 | AURKA Activation by TPX2 | 3.363064e-01 | 0.473 |
| R-HSA-5693606 | DNA Double Strand Break Response | 3.399815e-01 | 0.469 |
| R-HSA-9662360 | Sensory processing of sound by inner hair cells of the cochlea | 3.436364e-01 | 0.464 |
| R-HSA-376176 | Signaling by ROBO receptors | 3.476640e-01 | 0.459 |
| R-HSA-3000178 | ECM proteoglycans | 3.544814e-01 | 0.450 |
| R-HSA-9638482 | Metal ion assimilation from the host | 3.544814e-01 | 0.450 |
| R-HSA-372790 | Signaling by GPCR | 3.574199e-01 | 0.447 |
| R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes | 3.616128e-01 | 0.442 |
| R-HSA-380287 | Centrosome maturation | 3.686663e-01 | 0.433 |
| R-HSA-1169408 | ISG15 antiviral mechanism | 3.686663e-01 | 0.433 |
| R-HSA-9730414 | MITF-M-regulated melanocyte development | 3.695812e-01 | 0.432 |
| R-HSA-9659379 | Sensory processing of sound | 3.825429e-01 | 0.417 |
| R-HSA-9705683 | SARS-CoV-2-host interactions | 3.990012e-01 | 0.399 |
| R-HSA-2565942 | Regulation of PLK1 Activity at G2/M Transition | 3.994652e-01 | 0.399 |
| R-HSA-8939236 | RUNX1 regulates transcription of genes involved in differentiation of HSCs | 3.994652e-01 | 0.399 |
| R-HSA-5687128 | MAPK6/MAPK4 signaling | 4.027943e-01 | 0.395 |
| R-HSA-9909615 | Regulation of PD-L1(CD274) Post-translational modification | 4.061050e-01 | 0.391 |
| R-HSA-70268 | Pyruvate metabolism | 4.126722e-01 | 0.384 |
| R-HSA-5620912 | Anchoring of the basal body to the plasma membrane | 4.223886e-01 | 0.374 |
| R-HSA-983695 | Antigen activates B Cell Receptor (BCR) leading to generation of second messenge... | 4.350970e-01 | 0.361 |
| R-HSA-2029481 | FCGR activation | 4.350970e-01 | 0.361 |
| R-HSA-2730905 | Role of LAT2/NTAL/LAB on calcium mobilization | 4.475288e-01 | 0.349 |
| R-HSA-5607764 | CLEC7A (Dectin-1) signaling | 4.475288e-01 | 0.349 |
| R-HSA-9734767 | Developmental Cell Lineages | 4.650372e-01 | 0.333 |
| R-HSA-5653656 | Vesicle-mediated transport | 4.862382e-01 | 0.313 |
| R-HSA-202403 | TCR signaling | 4.917854e-01 | 0.308 |
| R-HSA-5693567 | HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 5.029829e-01 | 0.298 |
| R-HSA-2029485 | Role of phospholipids in phagocytosis | 5.112205e-01 | 0.291 |
| R-HSA-2871809 | FCERI mediated Ca+2 mobilization | 5.112205e-01 | 0.291 |
| R-HSA-2980736 | Peptide hormone metabolism | 5.166372e-01 | 0.287 |
| R-HSA-5693538 | Homology Directed Repair | 5.193232e-01 | 0.285 |
| R-HSA-8878166 | Transcriptional regulation by RUNX2 | 5.219944e-01 | 0.282 |
| R-HSA-195721 | Signaling by WNT | 5.267076e-01 | 0.278 |
| R-HSA-9717207 | Sensory perception of sweet, bitter, and umami (glutamate) taste | 5.325334e-01 | 0.274 |
| R-HSA-9851695 | Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | 5.402866e-01 | 0.267 |
| R-HSA-9841922 | MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesi... | 5.402866e-01 | 0.267 |
| R-HSA-9818564 | Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | 5.402866e-01 | 0.267 |
| R-HSA-9664323 | FCGR3A-mediated IL10 synthesis | 5.428427e-01 | 0.265 |
| R-HSA-9717189 | Sensory perception of taste | 5.578864e-01 | 0.253 |
| R-HSA-2187338 | Visual phototransduction | 6.001421e-01 | 0.222 |
| R-HSA-9758941 | Gastrulation | 6.045833e-01 | 0.219 |
| R-HSA-9694516 | SARS-CoV-2 Infection | 6.077589e-01 | 0.216 |
| R-HSA-5693532 | DNA Double-Strand Break Repair | 6.133198e-01 | 0.212 |
| R-HSA-9917777 | Epigenetic regulation by WDR5-containing histone modifying complexes | 6.154739e-01 | 0.211 |
| R-HSA-983705 | Signaling by the B Cell Receptor (BCR) | 6.239725e-01 | 0.205 |
| R-HSA-5633007 | Regulation of TP53 Activity | 6.281518e-01 | 0.202 |
| R-HSA-212436 | Generic Transcription Pathway | 6.500003e-01 | 0.187 |
| R-HSA-5621481 | C-type lectin receptors (CLRs) | 6.522805e-01 | 0.186 |
| R-HSA-9909648 | Regulation of PD-L1(CD274) expression | 6.542199e-01 | 0.184 |
| R-HSA-389948 | Co-inhibition by PD-1 | 7.043863e-01 | 0.152 |
| R-HSA-9640148 | Infection with Enterobacteria | 7.093143e-01 | 0.149 |
| R-HSA-73857 | RNA Polymerase II Transcription | 7.436951e-01 | 0.129 |
| R-HSA-8878171 | Transcriptional regulation by RUNX1 | 7.459222e-01 | 0.127 |
| R-HSA-3247509 | Chromatin modifying enzymes | 7.570810e-01 | 0.121 |
| R-HSA-202733 | Cell surface interactions at the vascular wall | 7.611395e-01 | 0.119 |
| R-HSA-4839726 | Chromatin organization | 7.767135e-01 | 0.110 |
| R-HSA-388841 | Regulation of T cell activation by CD28 family | 7.853302e-01 | 0.105 |
| R-HSA-1500931 | Cell-Cell communication | 8.469045e-01 | 0.072 |
| R-HSA-212165 | Epigenetic regulation of gene expression | 8.528371e-01 | 0.069 |
| R-HSA-1428517 | Aerobic respiration and respiratory electron transport | 8.670687e-01 | 0.062 |
| R-HSA-74160 | Gene expression (Transcription) | 8.733527e-01 | 0.059 |
| R-HSA-73894 | DNA Repair | 8.806157e-01 | 0.055 |
| R-HSA-6798695 | Neutrophil degranulation | 9.315651e-01 | 0.031 |
| R-HSA-3700989 | Transcriptional Regulation by TP53 | 9.346143e-01 | 0.029 |
| R-HSA-597592 | Post-translational protein modification | 9.617836e-01 | 0.017 |
| R-HSA-9709957 | Sensory Perception | 9.736869e-01 | 0.012 |
| R-HSA-392499 | Metabolism of proteins | 9.949722e-01 | 0.002 |
| R-HSA-1430728 | Metabolism | 1.000000e+00 | 0.000 |
Download
| kinase | JSD_mean | pearson_surrounding | kinase_max_IC_position | max_position_JSD |
|---|---|---|---|---|
EEF2K |
0.702 | 0.354 | 3 | 0.733 |
DSTYK |
0.687 | 0.335 | 2 | 0.723 |
GRK7 |
0.685 | 0.275 | 1 | 0.671 |
TNIK |
0.683 | 0.220 | 3 | 0.712 |
MST2 |
0.681 | 0.184 | 1 | 0.605 |
OSR1 |
0.681 | 0.203 | 2 | 0.655 |
MEKK2 |
0.679 | 0.103 | 2 | 0.669 |
COT |
0.678 | 0.206 | 2 | 0.711 |
PKR |
0.678 | 0.103 | 1 | 0.552 |
MLK4 |
0.677 | 0.180 | 2 | 0.670 |
ZAK |
0.677 | 0.169 | 1 | 0.631 |
MST3 |
0.676 | 0.160 | 2 | 0.738 |
MINK |
0.676 | 0.148 | 1 | 0.574 |
MST1 |
0.675 | 0.144 | 1 | 0.602 |
MEKK1 |
0.675 | 0.133 | 1 | 0.634 |
HGK |
0.674 | 0.156 | 3 | 0.691 |
MLK1 |
0.674 | 0.161 | 2 | 0.721 |
YSK4 |
0.674 | 0.117 | 1 | 0.571 |
TAO3 |
0.673 | 0.122 | 1 | 0.567 |
TTK |
0.673 | 0.123 | -2 | 0.747 |
ALK4 |
0.672 | 0.127 | -2 | 0.753 |
MLK3 |
0.671 | 0.164 | 2 | 0.700 |
MEKK3 |
0.670 | 0.057 | 1 | 0.587 |
DLK |
0.670 | 0.078 | 1 | 0.620 |
TAO2 |
0.670 | 0.121 | 2 | 0.717 |
BMPR2 |
0.670 | 0.053 | -2 | 0.753 |
MYO3A |
0.670 | 0.175 | 1 | 0.572 |
HRI |
0.669 | 0.135 | -2 | 0.763 |
ANKRD3 |
0.669 | 0.085 | 1 | 0.603 |
BRAF |
0.668 | 0.072 | -4 | 0.703 |
EGFR |
0.668 | 0.350 | 1 | 0.779 |
TGFBR1 |
0.668 | 0.136 | -2 | 0.738 |
ACVR2A |
0.668 | 0.118 | -2 | 0.753 |
GAK |
0.668 | 0.014 | 1 | 0.524 |
GRK6 |
0.667 | 0.124 | 1 | 0.649 |
NEK8 |
0.667 | 0.090 | 2 | 0.696 |
YSK1 |
0.667 | 0.117 | 2 | 0.710 |
ALK2 |
0.667 | 0.097 | -2 | 0.746 |
CDK2 |
0.667 | 0.252 | 1 | 0.496 |
NEK7 |
0.666 | 0.181 | -3 | 0.643 |
GCK |
0.666 | 0.076 | 1 | 0.556 |
MST4 |
0.666 | 0.158 | 2 | 0.708 |
NEK6 |
0.666 | 0.195 | -2 | 0.770 |
BMPR1B |
0.666 | 0.078 | 1 | 0.459 |
TAK1 |
0.666 | 0.043 | 1 | 0.545 |
NEK9 |
0.666 | 0.096 | 2 | 0.718 |
ACVR2B |
0.665 | 0.104 | -2 | 0.758 |
VRK2 |
0.665 | -0.065 | 1 | 0.607 |
CDK1 |
0.665 | 0.118 | 1 | 0.357 |
NIK |
0.663 | 0.000 | -3 | 0.587 |
CDK3 |
0.663 | 0.196 | 1 | 0.317 |
KHS2 |
0.663 | 0.100 | 1 | 0.557 |
VRK1 |
0.663 | 0.001 | 2 | 0.711 |
PRPK |
0.663 | -0.034 | -1 | 0.606 |
ULK2 |
0.663 | 0.130 | 2 | 0.644 |
NEK5 |
0.662 | 0.011 | 1 | 0.563 |
PLK1 |
0.662 | 0.066 | -2 | 0.728 |
PKCD |
0.662 | 0.106 | 2 | 0.706 |
ALPHAK3 |
0.662 | 0.074 | -1 | 0.627 |
TTBK2 |
0.662 | 0.073 | 2 | 0.637 |
KHS1 |
0.661 | 0.069 | 1 | 0.570 |
MOS |
0.661 | 0.021 | 1 | 0.493 |
MYO3B |
0.661 | 0.123 | 2 | 0.697 |
CLK3 |
0.661 | 0.135 | 1 | 0.511 |
CHAK2 |
0.661 | 0.090 | -1 | 0.575 |
CDK5 |
0.661 | 0.085 | 1 | 0.384 |
PKN2 |
0.661 | 0.103 | -3 | 0.529 |
PERK |
0.660 | 0.050 | -2 | 0.755 |
GRK1 |
0.660 | 0.141 | -2 | 0.632 |
GRK5 |
0.660 | 0.070 | -3 | 0.625 |
BMPR2_TYR |
0.658 | 0.196 | -1 | 0.699 |
MEK5 |
0.658 | -0.061 | 2 | 0.650 |
LATS1 |
0.658 | 0.049 | -3 | 0.550 |
MEK1 |
0.658 | -0.073 | 2 | 0.644 |
SYK |
0.658 | 0.269 | -1 | 0.723 |
LRRK2 |
0.658 | 0.016 | 2 | 0.695 |
RAF1 |
0.657 | -0.007 | 1 | 0.584 |
TLK1 |
0.657 | 0.052 | -2 | 0.757 |
PRP4 |
0.657 | 0.051 | -3 | 0.638 |
PKN3 |
0.657 | 0.035 | -3 | 0.518 |
FLT1 |
0.656 | 0.254 | -1 | 0.728 |
CHAK1 |
0.655 | 0.086 | 2 | 0.625 |
NLK |
0.655 | -0.005 | 1 | 0.517 |
MAP3K15 |
0.655 | -0.024 | 1 | 0.591 |
TGFBR2 |
0.655 | 0.078 | -2 | 0.749 |
NEK1 |
0.655 | -0.009 | 1 | 0.562 |
MUSK |
0.655 | 0.309 | 1 | 0.769 |
EPHA6 |
0.655 | 0.183 | -1 | 0.703 |
CAMKK1 |
0.655 | -0.024 | -2 | 0.587 |
NEK2 |
0.654 | 0.070 | 2 | 0.701 |
FLT3 |
0.654 | 0.189 | 3 | 0.550 |
ERBB2 |
0.653 | 0.255 | 1 | 0.745 |
PLK2 |
0.653 | 0.084 | -3 | 0.659 |
BMPR1A |
0.653 | 0.052 | 1 | 0.459 |
ATR |
0.653 | -0.032 | 1 | 0.541 |
HPK1 |
0.653 | 0.018 | 1 | 0.549 |
EPHB4 |
0.652 | 0.148 | -1 | 0.664 |
ULK1 |
0.652 | 0.078 | -3 | 0.616 |
TAO1 |
0.652 | 0.088 | 1 | 0.552 |
CAMK2G |
0.652 | -0.011 | 2 | 0.580 |
ASK1 |
0.652 | -0.024 | 1 | 0.593 |
PKCB |
0.652 | 0.110 | 2 | 0.704 |
CAMK1B |
0.651 | -0.053 | -3 | 0.563 |
PKCA |
0.651 | 0.113 | 2 | 0.695 |
KDR |
0.651 | 0.179 | 3 | 0.463 |
GRK4 |
0.651 | 0.075 | -2 | 0.717 |
MEKK6 |
0.651 | -0.031 | 1 | 0.577 |
PKCH |
0.651 | 0.089 | 2 | 0.685 |
PASK |
0.651 | 0.008 | -3 | 0.555 |
ERBB4 |
0.651 | 0.302 | 1 | 0.801 |
NEK11 |
0.651 | -0.047 | 1 | 0.575 |
FRK |
0.650 | 0.193 | -1 | 0.569 |
PDK1 |
0.650 | -0.066 | 1 | 0.528 |
CDKL1 |
0.650 | -0.023 | -3 | 0.518 |
NEK4 |
0.650 | -0.028 | 1 | 0.568 |
TYK2 |
0.650 | 0.119 | 1 | 0.634 |
GRK2 |
0.650 | 0.018 | -2 | 0.628 |
JNK3 |
0.649 | -0.032 | 1 | 0.375 |
ZAP70 |
0.649 | 0.260 | -1 | 0.629 |
PLK3 |
0.649 | 0.028 | 2 | 0.551 |
CAMLCK |
0.649 | -0.091 | -2 | 0.652 |
SRPK3 |
0.648 | 0.046 | -3 | 0.455 |
MLK2 |
0.648 | -0.068 | 2 | 0.678 |
IRE1 |
0.648 | 0.028 | 1 | 0.506 |
PKCG |
0.648 | 0.104 | 2 | 0.706 |
HUNK |
0.648 | -0.034 | 2 | 0.692 |
IRE2 |
0.648 | 0.043 | 2 | 0.654 |
STLK3 |
0.648 | -0.014 | 1 | 0.609 |
TLK2 |
0.647 | -0.049 | 1 | 0.581 |
KIT |
0.647 | 0.115 | 3 | 0.508 |
MET |
0.647 | 0.161 | 3 | 0.482 |
MST1R |
0.647 | 0.121 | 3 | 0.516 |
CSF1R |
0.647 | 0.090 | 3 | 0.503 |
FGFR4 |
0.647 | 0.159 | -1 | 0.625 |
LCK |
0.647 | 0.100 | -1 | 0.579 |
JAK3 |
0.646 | 0.146 | 1 | 0.584 |
WNK1 |
0.646 | -0.003 | -2 | 0.681 |
PDGFRB |
0.645 | 0.116 | 3 | 0.541 |
RET |
0.645 | 0.065 | 1 | 0.622 |
ERK7 |
0.645 | 0.102 | 2 | 0.616 |
PTK2 |
0.645 | 0.184 | -1 | 0.756 |
TNNI3K_TYR |
0.645 | 0.168 | 1 | 0.632 |
PINK1 |
0.645 | 0.010 | 1 | 0.478 |
EPHB2 |
0.645 | 0.133 | -1 | 0.652 |
JAK2 |
0.645 | 0.071 | 1 | 0.622 |
GCN2 |
0.645 | 0.049 | 2 | 0.642 |
HASPIN |
0.645 | 0.020 | -1 | 0.456 |
DAPK2 |
0.645 | -0.122 | -3 | 0.570 |
IRAK4 |
0.645 | -0.016 | 1 | 0.535 |
BLK |
0.645 | 0.081 | -1 | 0.584 |
MATK |
0.645 | 0.112 | -1 | 0.532 |
MTOR |
0.645 | -0.034 | 1 | 0.542 |
WEE1_TYR |
0.644 | 0.107 | -1 | 0.504 |
GRK3 |
0.644 | 0.050 | -2 | 0.601 |
FGR |
0.644 | 0.068 | 1 | 0.597 |
ROS1 |
0.644 | 0.072 | 3 | 0.522 |
PDHK1 |
0.644 | -0.055 | 1 | 0.618 |
PINK1_TYR |
0.644 | 0.067 | 1 | 0.555 |
EPHB1 |
0.644 | 0.111 | 1 | 0.638 |
P38G |
0.644 | -0.023 | 1 | 0.303 |
NUAK2 |
0.644 | -0.003 | -3 | 0.527 |
TBK1 |
0.644 | -0.049 | 1 | 0.594 |
LOK |
0.643 | 0.006 | -2 | 0.591 |
CDK6 |
0.643 | 0.062 | 1 | 0.348 |
FYN |
0.643 | 0.122 | -1 | 0.585 |
PDHK3_TYR |
0.643 | -0.001 | 4 | 0.653 |
GSK3B |
0.643 | 0.035 | 4 | 0.464 |
EPHA8 |
0.643 | 0.165 | -1 | 0.643 |
PKCE |
0.642 | 0.107 | 2 | 0.707 |
JAK1 |
0.642 | 0.071 | 1 | 0.606 |
TSSK2 |
0.642 | -0.030 | -5 | 0.722 |
IKKE |
0.642 | -0.031 | 1 | 0.598 |
IKKB |
0.642 | -0.013 | -2 | 0.611 |
ABL2 |
0.642 | 0.041 | -1 | 0.554 |
HCK |
0.642 | 0.062 | -1 | 0.564 |
FLT4 |
0.642 | 0.145 | 3 | 0.443 |
FGFR2 |
0.642 | 0.141 | 3 | 0.480 |
GSK3A |
0.641 | 0.041 | 4 | 0.472 |
PIM3 |
0.641 | -0.035 | -3 | 0.535 |
PDHK4 |
0.640 | -0.165 | 1 | 0.583 |
CAMKK2 |
0.640 | -0.106 | -2 | 0.567 |
YES1 |
0.640 | 0.042 | -1 | 0.557 |
ITK |
0.640 | 0.041 | -1 | 0.521 |
INSRR |
0.640 | 0.055 | 3 | 0.472 |
BIKE |
0.640 | -0.022 | 1 | 0.446 |
BMX |
0.640 | 0.032 | -1 | 0.503 |
PIM1 |
0.640 | -0.020 | -3 | 0.484 |
WNK4 |
0.640 | -0.070 | -2 | 0.683 |
PDHK1_TYR |
0.639 | 0.006 | -1 | 0.672 |
PKMYT1_TYR |
0.639 | -0.057 | 3 | 0.547 |
JNK2 |
0.639 | -0.051 | 1 | 0.340 |
EPHB3 |
0.639 | 0.073 | -1 | 0.637 |
MAP2K6_TYR |
0.639 | -0.010 | -1 | 0.655 |
ERK5 |
0.639 | -0.082 | 1 | 0.443 |
RIPK3 |
0.639 | -0.109 | 3 | 0.441 |
ATM |
0.638 | -0.011 | 1 | 0.503 |
SRPK1 |
0.638 | 0.015 | -3 | 0.468 |
MAP2K4_TYR |
0.638 | -0.022 | -1 | 0.641 |
MEK2 |
0.638 | -0.122 | 2 | 0.622 |
NTRK3 |
0.638 | 0.096 | -1 | 0.610 |
PDGFRA |
0.638 | 0.095 | 3 | 0.556 |
NEK3 |
0.637 | -0.016 | 1 | 0.566 |
TESK1_TYR |
0.637 | -0.058 | 3 | 0.601 |
EPHA4 |
0.637 | 0.066 | 2 | 0.554 |
PKCZ |
0.637 | 0.025 | 2 | 0.703 |
FER |
0.637 | 0.022 | 1 | 0.614 |
EPHA7 |
0.637 | 0.076 | 2 | 0.573 |
SMMLCK |
0.637 | -0.067 | -3 | 0.511 |
INSR |
0.637 | 0.071 | 3 | 0.454 |
ABL1 |
0.637 | 0.015 | -1 | 0.533 |
TTBK1 |
0.637 | 0.003 | 2 | 0.564 |
FGFR1 |
0.637 | 0.102 | 3 | 0.466 |
P70S6KB |
0.637 | -0.021 | -3 | 0.490 |
DRAK1 |
0.636 | -0.059 | 1 | 0.462 |
NTRK1 |
0.636 | 0.083 | -1 | 0.635 |
SLK |
0.636 | -0.013 | -2 | 0.546 |
EPHA2 |
0.636 | 0.159 | -1 | 0.675 |
SRC |
0.636 | 0.096 | -1 | 0.557 |
TYRO3 |
0.636 | -0.018 | 3 | 0.552 |
TXK |
0.636 | 0.006 | 1 | 0.520 |
IKKA |
0.636 | -0.002 | -2 | 0.608 |
MPSK1 |
0.635 | -0.070 | 1 | 0.459 |
FGFR3 |
0.635 | 0.117 | 3 | 0.458 |
ICK |
0.635 | -0.086 | -3 | 0.537 |
RSK2 |
0.635 | 0.003 | -3 | 0.466 |
JNK1 |
0.635 | -0.033 | 1 | 0.354 |
PKCT |
0.634 | 0.039 | 2 | 0.678 |
EPHA5 |
0.634 | 0.113 | 2 | 0.526 |
MAP2K7_TYR |
0.634 | -0.165 | 2 | 0.633 |
MASTL |
0.634 | -0.213 | -2 | 0.636 |
P38A |
0.634 | -0.073 | 1 | 0.383 |
PDHK4_TYR |
0.633 | -0.078 | 2 | 0.605 |
P38B |
0.633 | -0.058 | 1 | 0.360 |
CK1A2 |
0.633 | 0.036 | -3 | 0.416 |
CK1D |
0.633 | 0.033 | -3 | 0.422 |
CSK |
0.633 | 0.065 | 2 | 0.575 |
ALK |
0.633 | 0.027 | 3 | 0.466 |
NTRK2 |
0.633 | 0.065 | 3 | 0.449 |
P38D |
0.632 | -0.032 | 1 | 0.293 |
CDKL5 |
0.632 | -0.032 | -3 | 0.506 |
AAK1 |
0.632 | 0.000 | 1 | 0.362 |
LKB1 |
0.632 | -0.165 | -3 | 0.589 |
BTK |
0.631 | -0.012 | -1 | 0.454 |
TEC |
0.631 | -0.008 | -1 | 0.448 |
SRMS |
0.631 | -0.012 | 1 | 0.624 |
AKT2 |
0.631 | -0.006 | -3 | 0.390 |
SGK3 |
0.631 | -0.021 | -3 | 0.444 |
CAMK2B |
0.631 | -0.018 | 2 | 0.526 |
LYN |
0.631 | 0.018 | 3 | 0.440 |
CLK1 |
0.630 | 0.029 | -3 | 0.433 |
IRAK1 |
0.630 | -0.102 | -1 | 0.447 |
TSSK1 |
0.630 | -0.061 | -3 | 0.546 |
SKMLCK |
0.630 | -0.142 | -2 | 0.652 |
RIPK1 |
0.630 | -0.202 | 1 | 0.546 |
IGF1R |
0.630 | 0.064 | 3 | 0.399 |
AMPKA1 |
0.630 | -0.097 | -3 | 0.532 |
EPHA3 |
0.629 | 0.053 | 2 | 0.535 |
TEK |
0.629 | 0.027 | 3 | 0.488 |
DCAMKL1 |
0.629 | -0.075 | -3 | 0.452 |
LTK |
0.629 | -0.008 | 3 | 0.456 |
DMPK1 |
0.629 | -0.050 | -3 | 0.436 |
CLK2 |
0.628 | 0.038 | -3 | 0.457 |
BUB1 |
0.628 | -0.016 | -5 | 0.636 |
PLK4 |
0.628 | -0.075 | 2 | 0.476 |
MNK1 |
0.628 | 0.006 | -2 | 0.606 |
LIMK1_TYR |
0.628 | -0.079 | 2 | 0.668 |
CDK16 |
0.628 | -0.004 | 1 | 0.330 |
RSK3 |
0.628 | -0.012 | -3 | 0.460 |
CLK4 |
0.628 | -0.019 | -3 | 0.474 |
PKCI |
0.628 | 0.041 | 2 | 0.705 |
ROCK2 |
0.628 | -0.063 | -3 | 0.475 |
AKT1 |
0.627 | -0.007 | -3 | 0.397 |
CK1E |
0.627 | 0.022 | -3 | 0.462 |
CDC7 |
0.627 | -0.159 | 1 | 0.465 |
LIMK2_TYR |
0.626 | -0.095 | -3 | 0.598 |
DAPK3 |
0.626 | -0.098 | -3 | 0.486 |
WNK3 |
0.626 | -0.171 | 1 | 0.574 |
STK33 |
0.626 | -0.039 | 2 | 0.512 |
RIPK2 |
0.626 | -0.082 | 1 | 0.578 |
P90RSK |
0.625 | -0.044 | -3 | 0.483 |
CDK13 |
0.625 | -0.046 | 1 | 0.354 |
CAMK2D |
0.625 | -0.096 | -3 | 0.517 |
DNAPK |
0.625 | -0.085 | 1 | 0.479 |
SRPK2 |
0.625 | 0.013 | -3 | 0.399 |
BCKDK |
0.624 | -0.066 | -1 | 0.550 |
DCAMKL2 |
0.624 | -0.076 | -3 | 0.480 |
EPHA1 |
0.624 | -0.011 | 3 | 0.471 |
PIM2 |
0.624 | -0.046 | -3 | 0.439 |
PBK |
0.624 | -0.093 | 1 | 0.469 |
ERK2 |
0.623 | -0.086 | 1 | 0.367 |
DDR1 |
0.623 | -0.089 | 4 | 0.566 |
CDK10 |
0.623 | 0.011 | 1 | 0.353 |
CDK4 |
0.623 | -0.013 | 1 | 0.344 |
CDK14 |
0.623 | -0.035 | 1 | 0.382 |
RSK4 |
0.623 | -0.018 | -3 | 0.446 |
CHK1 |
0.623 | -0.109 | -3 | 0.508 |
ERK1 |
0.623 | -0.066 | 1 | 0.332 |
MERTK |
0.623 | -0.047 | 3 | 0.443 |
YANK3 |
0.623 | -0.003 | 2 | 0.329 |
CK2A2 |
0.622 | 0.013 | 1 | 0.331 |
CDK12 |
0.622 | -0.047 | 1 | 0.343 |
FAM20C |
0.622 | 0.016 | 2 | 0.381 |
CAMK2A |
0.622 | -0.033 | 2 | 0.559 |
CDK17 |
0.621 | -0.041 | 1 | 0.316 |
MAPKAPK2 |
0.621 | 0.036 | -3 | 0.412 |
CDK8 |
0.621 | -0.066 | 1 | 0.410 |
HIPK1 |
0.621 | -0.074 | 1 | 0.428 |
NDR1 |
0.620 | -0.080 | -3 | 0.523 |
CDK18 |
0.620 | -0.035 | 1 | 0.331 |
AXL |
0.620 | -0.080 | 3 | 0.456 |
MAPKAPK3 |
0.620 | -0.061 | -3 | 0.443 |
MARK4 |
0.620 | -0.145 | 4 | 0.512 |
TNK2 |
0.620 | -0.099 | 3 | 0.470 |
PAK1 |
0.620 | -0.094 | -2 | 0.553 |
DAPK1 |
0.620 | -0.090 | -3 | 0.480 |
PHKG2 |
0.619 | 0.021 | -3 | 0.467 |
MNK2 |
0.619 | -0.029 | -2 | 0.588 |
ROCK1 |
0.619 | -0.058 | -3 | 0.440 |
PHKG1 |
0.618 | -0.026 | -3 | 0.502 |
PKG2 |
0.618 | -0.012 | -2 | 0.529 |
SMG1 |
0.618 | -0.115 | 1 | 0.505 |
MRCKB |
0.618 | -0.059 | -3 | 0.423 |
PKACG |
0.617 | -0.048 | -2 | 0.578 |
CAMK4 |
0.617 | -0.119 | -3 | 0.497 |
AMPKA2 |
0.617 | -0.111 | -3 | 0.498 |
PTK6 |
0.617 | -0.100 | -1 | 0.463 |
KIS |
0.616 | 0.002 | 1 | 0.402 |
PKN1 |
0.616 | 0.003 | -3 | 0.407 |
CHK2 |
0.616 | -0.047 | -3 | 0.328 |
DYRK2 |
0.616 | -0.091 | 1 | 0.419 |
PRKD1 |
0.615 | -0.068 | -3 | 0.485 |
PRKD3 |
0.615 | -0.054 | -3 | 0.412 |
MRCKA |
0.615 | -0.057 | -3 | 0.439 |
AURA |
0.615 | -0.048 | -2 | 0.427 |
DDR2 |
0.615 | -0.017 | 3 | 0.459 |
TNK1 |
0.615 | -0.108 | 3 | 0.509 |
SGK1 |
0.614 | -0.037 | -3 | 0.332 |
CAMK1G |
0.614 | -0.078 | -3 | 0.448 |
MSK2 |
0.614 | -0.065 | -3 | 0.446 |
YANK2 |
0.613 | -0.010 | 2 | 0.352 |
SSTK |
0.613 | -0.083 | 4 | 0.481 |
CK1G1 |
0.613 | 0.008 | -3 | 0.471 |
MELK |
0.613 | -0.127 | -3 | 0.477 |
PAK3 |
0.613 | -0.128 | -2 | 0.552 |
MYLK4 |
0.613 | -0.107 | -2 | 0.570 |
NIM1 |
0.612 | -0.149 | 3 | 0.506 |
NDR2 |
0.612 | -0.071 | -3 | 0.526 |
PRKD2 |
0.612 | -0.047 | -3 | 0.429 |
CK2A1 |
0.611 | -0.012 | 1 | 0.314 |
PAK2 |
0.611 | -0.146 | -2 | 0.539 |
NUAK1 |
0.610 | -0.085 | -3 | 0.471 |
CDK9 |
0.609 | -0.081 | 1 | 0.364 |
AKT3 |
0.609 | -0.014 | -3 | 0.336 |
PTK2B |
0.609 | -0.070 | -1 | 0.469 |
NEK10_TYR |
0.609 | -0.151 | 1 | 0.430 |
QIK |
0.609 | -0.164 | -3 | 0.517 |
MSK1 |
0.608 | -0.064 | -3 | 0.449 |
MAK |
0.608 | -0.068 | -2 | 0.495 |
AURB |
0.608 | -0.075 | -2 | 0.471 |
MAPKAPK5 |
0.608 | -0.065 | -3 | 0.424 |
CDK19 |
0.607 | -0.072 | 1 | 0.380 |
CK1G2 |
0.607 | 0.053 | -3 | 0.406 |
FES |
0.607 | -0.010 | -1 | 0.484 |
PKACB |
0.607 | -0.046 | -2 | 0.511 |
HIPK3 |
0.606 | -0.112 | 1 | 0.425 |
P70S6K |
0.606 | -0.061 | -3 | 0.407 |
AURC |
0.604 | -0.053 | -2 | 0.481 |
LATS2 |
0.603 | -0.105 | -5 | 0.523 |
QSK |
0.603 | -0.129 | 4 | 0.483 |
SIK |
0.602 | -0.108 | -3 | 0.436 |
DYRK1A |
0.602 | -0.112 | 1 | 0.420 |
PAK6 |
0.601 | -0.032 | -2 | 0.479 |
CRIK |
0.601 | -0.089 | -3 | 0.389 |
HIPK2 |
0.601 | -0.082 | 1 | 0.329 |
CDK7 |
0.601 | -0.106 | 1 | 0.365 |
CK1G3 |
0.600 | 0.002 | -3 | 0.342 |
DYRK3 |
0.600 | -0.103 | 1 | 0.440 |
MOK |
0.600 | -0.092 | 1 | 0.400 |
PRKX |
0.600 | -0.006 | -3 | 0.383 |
DYRK1B |
0.600 | -0.103 | 1 | 0.393 |
MARK3 |
0.599 | -0.135 | 4 | 0.435 |
MARK2 |
0.599 | -0.159 | 4 | 0.386 |
HIPK4 |
0.599 | -0.149 | 1 | 0.442 |
CAMK1D |
0.597 | -0.113 | -3 | 0.359 |
MARK1 |
0.597 | -0.166 | 4 | 0.460 |
DYRK4 |
0.594 | -0.095 | 1 | 0.353 |
PKACA |
0.594 | -0.052 | -2 | 0.474 |
SNRK |
0.594 | -0.189 | 2 | 0.488 |
CAMK1A |
0.593 | -0.089 | -3 | 0.335 |
SBK |
0.589 | -0.078 | -3 | 0.277 |
BRSK1 |
0.586 | -0.152 | -3 | 0.462 |
CK1A |
0.585 | 0.015 | -3 | 0.372 |
BRSK2 |
0.584 | -0.185 | -3 | 0.481 |
PAK5 |
0.581 | -0.087 | -2 | 0.399 |
PAK4 |
0.575 | -0.077 | -2 | 0.395 |
PKG1 |
0.572 | -0.065 | -2 | 0.477 |